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The ARF tumor suppressor is upregulated upon oncogenic stress. ARF can
suppress cell proliferation in both p53-dependent and -independent mechanisms. We
have focused on ARF’s ability to suppress protein synthesis in a p53-independent
manner. Given that protein synthesis and the cell cycle are coordinately controlled, this
arm of ARF tumor suppression also contributes to the restraint of cell proliferation. Our
lab has recently shown that basal ARF suppresses protein synthesis in mitotic cells. The
focus of my dissertation has been to determine whether basal ARF regulates cell growth
in a post-mitotic setting.
We used the osteoclast (OC) as a model for post-mitotic growth. We attempted to
generate osteoclast-specific Arf loss using a Cre-expressing mouse, in which Cre is
controlled by the Cathepsin K promoter (CtskCre/+). Surprisingly, we generated Arf -/- mice
as demonstrated by genotyping, loss of ARF expression in the testis, and a phenotype
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comparable to traditional Arf -/- mice. Furthermore, both Cathepsin K and Cre are
expressed in reproductive tissues, which results in Cre activity within gametes as
confirmed by crossing CtskCre/+ mice with ROSA reporter mice. Finally, we found that
Cathepsin K loss enhances serum estradiol levels. Together, this data suggests that
Cathepsin K-driven Cre will not consistently result in OC-specific gene loss and may
lead to misinterpretation of phenotypes generated to study the function of OC genes.
In parallel, we have analyzed the role of ARF during osteoclastogenesis in vitro
and found that Arf loss enhances osteoclastogenesis as demonstrated by OC number and
size, protein markers of osteoclastogenesis, and increased bone resorption. Enhanced
osteoclastogenesis upon Arf loss is independent of both proliferation and p53.
Furthermore, we demonstrated enhanced protein synthesis and ribosome activity during
osteoclastogenesis in Arf -/- cells. As an alternative approach to studying Arf loss in vivo,
we generated radiation chimeras and challenged them with RANKL. We found that Arf
loss results in elevated bone resorption due, at least in part, to increased
osteoclastogenesis in vivo. This data collectively suggests that ARF regulates
proliferation-independent cell growth, a function that is physiologically relevant both in
vitro and in vivo.
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Chapter 1
Introduction
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1.1 Unrestrained growth: a hallmark of cancer
There is no precise formula that drives a normal cell to become neoplastic. However,
there are certain characteristics common among cancerous cells that have been described
by Hanahan and Weinberg as the hallmarks of cancer. The founding hallmark capabilities
include the ability to sustain proliferative signaling, evade growth suppressors, activate
invasion and metastasis, enable replicative immortality, induce angiogenesis, and resist
cell death (Hanahan and Weinberg, 2000). A decade later, additional hallmarks have been
added to the original six, including reprogramming of energy metabolism and evading
immune destruction. It is now also clear that genetic alterations largely underpin the
ability of normal cells to acquire these characteristics. Furthermore, we must not only
consider the individual cell but also the surrounding cells and tissues, known as the tumor
microenvironment (Hanahan and Weinberg, 2011). My dissertation largely centers
around two of the original cancer hallmarks: the ability to sustain proliferative signaling
and the ability to evade growth suppression. Throughout this introduction, I will focus on
cell growth (i.e. protein translation) as an essential and distinct component of
proliferation. It will be important to remember that growth is just as necessary to
proliferation as is the completion of mitosis; for without an increase in cell mass,
daughter cells would become progressively smaller until they conceivably become
nonfunctional and die.
Instructing a cell to grow via mTOR
In a normal cell, growth is only initiated when the proper nutrients and signals are
present. The target of rapamycin (TOR) is a cellular sensor for signals that instruct a cell
to grow. TOR (mTOR in mammals, also known as FRAP, RAFT, RAPT, or SEP) is an
2

evolutionarily conserved serine/threonine kinase and member of the phosphatidylinositol
3-kinase (PI3K)-related kinase (PIKK) superfamily (Brown et al., 1994; Chen et al.,
1994; Chiu et al., 1994; Keith and Schreiber, 1995; Sabatini et al., 1995; Sabers et al.,
1995). As its name suggests, TOR is bound by the bacterial compound rapamycin
(Sehgal, 2003). In mammals, the binding of rapamycin to its target suppresses
proliferation, emphasizing the importance of the mTOR pathway in regulating this
process. To promote growth, mTOR shuttles from the cytoplasm to the nucleus, where it
regulates two major proteins involved in translation: S6 kinase 1 (S6K1) and 4E-BP1
(eukaryotic initiation factor 4E (eIF4E)-binding protein, also known as PHAS-1) (Kim
and Chen, 2000).
Phosphorylation of S6K1 by mTOR results in the subsequent phosphorylation of
40S ribosomal protein S6 (Jeno et al., 1988). It has been suggested that the
phosphorylation of S6 is important for the enhanced translational efficiency of 5'-TOP
(terminal oligopyrimidine)-containing mRNAs (Jefferies et al., 1997; Jefferies et al.,
1994; Terada et al., 1994). Importantly, many components of the translational machinery
contain a 5'-TOP sequence, thus the phosphorylation of S6K1 may result in an overall
enhancement of protein synthesis. While this is an intriguing hypothesis, it has also been
questioned by results demonstrating that S6K1 activity and S6 phosphorylation are
dispensable in the upregulation of 5'-TOP mRNA translation. Furthermore, S6K1 is
known to have other, albeit less-well studied, substrates that may contribute to enhanced
protein synthesis (Fingar and Blenis, 2004; Ruvinsky and Meyuhas, 2006). So, while it is
clear the S6K1 is important for cell growth, we do not yet fully understand the
mechanism by which it exerts its functions.
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In the absence of mTOR activation, 4E-BP1 binds tightly to eIF4E and inhibits its
association with eIF4G to prevent the eIF4F complex from forming and thus protein
synthesis from occurring. Upon phosphorylation by mTOR, 4E-BP1 releases eIF4E and
allows for binding of eIF4E with eIF4G (Marcotrigiano et al., 1999), which is a
scaffolding protein that recruits additional members of the initiation complex to promote
cap-dependent translation. Clearly, 4E-BP1 and S6K1 are important modulators
downstream of mTOR that instruct a cell to grow. As I mentioned above, cell growth is
the production of macromolecules, and thus, in the next section I will give an overview of
how the machinery for protein synthesis comes together.

The machinery for protein synthesis
Protein translation begins in nucleoli with the production of ribosomes. Nucleoli
are composed of three structural regions: the fibrillar center, the dense fibrillar
component, and the granular component. RNA polymerase I (Pol 1), HMG1 box
architectural upstream binding factor (UBF), and the selectivity complex (SL1, also
known as TIF-IB) are located in fibrillar centers, and this is where the transcription of
ribosomal DNA (rDNA) occurs. With the exception of the 5S rRNA , all rRNAs all
encoded in a polycistronic message (Fatica and Tollervey, 2002). The 5S subunit is
separately transcribed by RNA polymerase III. The rRNA is then modified and
processed by small nucleolar RNAs (snoRNAs), which guide both 2'-O-methylation and
pseudouridylation (with the enzyme dyskerin) of individual nucleotides (Kiss, 2001).
Subsequent cleavage by RNases eventually results in the mature ribosomal components.
The 18S rRNA combines with ribosomal proteins to form the 40S ribosomal subunit
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while the 60S subunit is formed by the joining of ribosomal proteins with 5S, 5.8S, and
28S subunits. The granular component is the site at which preribosomal subunits
assemble with ribosomal proteins (Ruggero and Pandolfi, 2003). Finally, the small (40S)
and large (60S) ribosomal subunits are ready to be transported to the cytoplasm for
protein translation (Figure 1.1).

The ARF tumor suppressor: a sensor and modulator of cell growth
Given the importance of cell growth to tumor progression, it is important to
understand the mechanisms by which a cell regulates ribosome production and protein
synthesis. The ARF tumor suppressor is a key sensor of signals that instruct a cell to
grow and is appropriately localized in nucleoli to limit unrestrained growth. In the
following sections, I will introduce the ARF tumor suppressor, explain its known
relevance in cancer, and highlight what is known about how it responds to cell growth
signals.

1.2 ARF expression
The INK4a/Arf locus: organization and regulation
ARF is encoded on chromosome 9p21 as part of the CDKN2a, which includes
both INK4a and Arf (Figure 1.2). The locus also contains INK4b (also known as
CDKN2b), which lies upstream of Arf and INK4a. INK4b is its own genetic entity, while
INK4a and Arf share two of their three exons (Quelle et al., 1995; Sherr, 2000). It is also
worth noting that a non-coding RNA, ANRIL (also known as CDKN2b antisense or
CDKN2BAS), has recently been discovered at the INK4b-Arf-INK4a locus. It has been
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proposed that ANRIL regulates the expression of the locus (Pasmant et al., 2007). Due to
splicing events, unique promoters, and unique first exons, the transcription products of
INK4a and Arf contain distinctive first exons (INK4a is encoded by exon 1α and Arf is
encoded by exon 1β) but identical second and third exons. The two shared exons result in
almost 70% sequence homology at the DNA level. However, Arf is translated in an
alternative reading frame, for which it is named, from that of INK4a (Quelle et al., 1995).
This results in two proteins that are distinctive following translation.
Both p15INK4b and p16INK4a bind and inhibit the cyclin-dependent kinases, CDK4
and CDK6 (Serrano et al., 1993; Sharpless, 2005). These kinases are important for the
hyperphosphorylation of the retinoblastoma (Rb) tumor suppressor. When CDK4/6 are
inhibited by p15INK4b and p16INK4a, Rb is in a hypophosphorylated state, allowing it to
bind and inhibit transcription factors of the E2F family (Sherr, 1996). Thus, p15INK4b and
p16INK4a effectively halt the progression from G1 to S in the cell cycle. The first
discovered role for ARF was also in regulating cell cycle progression as I will discuss
further in the next section.

Regulating the Arf locus
Under normal conditions, it is important to keep Arf (and other members of the
locus) repressed. This is primarily accomplished by polycomb repressive complexes
(PRC). Generally speaking, the PRC2 complex first specifically methylates histone H3 at
lysine 27, a process catalyzed by EZH2. The chromatin mark is then recognized by
PRC1, which subsequently ubiquitinates histone H2A (Cao et al., 2002; Wang et al.,
2004). The importance of this process in repressing Arf is evident by studies
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demonstrating that overexpression of polycomb group (PcG) members retards senescence
(Dietrich et al., 2007; Gil et al., 2004; Jacobs et al., 1999). In the case of Bmi-1 (a PcG
member) overexpression, mouse embryonic fibroblasts (MEFs) become immortalized in
culture. Furthermore, bmi-1-/- MEFs have heightened levels of ARF (and p16INK4a) and
are unable to enter S phase (Jacobs et al., 1999) . Upon oncogenic stress, it is important
that a cell quickly be able to respond by upregulating the expression of ARF. This seems
to be accomplished by a coordination of various factors and the exact mechanism may be
different for different types of tissues or dependent upon the type of stress. For example,
the expression of the methylating protein EZH2 can be downregulated (Bracken et al.,
2007). Histone H3 can also be demethylated by demethylase enzymes such as JMJD3,
which is upregulated in response to oncogenic Ras (Agger et al., 2009; Barradas et al.,
2009). Finally, in selective tissues, oncogenic stress can cause the derepression of Arf by
upregulating members of the chromatin remodeling SWI/SNF complex (Young and
Jacks).

Arf loss in cancer
Mice containing individual loss of each of the three aforementioned genes have
revealed that all are important in tumor suppression. p16INK4a and ARF have synergistic
tumor suppressive functions as mice containing loss of both are more tumor prone than
those with the loss of only one or the other (Sharpless et al., 2004). Given the scope of
my work, I will focus on alterations to Arf in cancer.
In order to specifically determine the role of Arf in tumor suppression, Sherr and
colleagues selectively disrupted exon 1β in mice. These mice began developing tumors as
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early as 8 weeks. After one year, 80% of the mice had died from spontaneous tumor
development, with a mean survival latency of 38 weeks. Heterozygous mice also
developed tumors, albeit after a longer latency compared to Arf -/- mice. Upon
examination of Arf +/- mice, it was noted that tumor formation was accompanied by loss
of the remaining allele. The tumor spectrum in Arf -/- mice included sarcomas (43%),
lymphoid malignancies (29%), carcinomas (17%), and tumors of the nervous system
(11%) (Kamijo et al., 1999). Consistent with this data is the work showing that mouse
embryonic fibroblasts taken from Arf -/- mice are immortal and transformed upon the
ectopic expression of oncogenic Ras (Kamijo et al., 1997). Furthermore, as wild-type
cells are passaged, the expression of ARF increases, implying a role for ARF in limiting
the proliferation of cultured cells.
In human cancers, one of the most frequent cytogenetic events is the homozygous
loss of the INK4b-Arf-INK4a locus. In fact, the frequency of mutation at this locus is
second only to the p53 locus (Hainaut et al., 1997; Hall and Peters, 1996). In most cases
of human cancer, all three proteins of the INK4b-Arf-INK4a locus are lost, making it
difficult to determine their individual roles in human tumor suppression. However, there
are specific examples in which only Arf appears to be affected in human cancer, and these
cases appear to be most common in melanoma patients. Gene deletions in family with
melanoma-neural system tumor syndrome have been shown to occur specifically in exon
1β (Randerson-Moor et al., 2001). Deletion of exon 1β has also been reported in
members of a family predisposed to melanoma (Laud et al., 2006). In addition to
melanoma cases, it has been reported that nine of fifty glioblastoma patients had specific
deletion of Arf (Nakamura et al., 2001). Aside from deletions, mutations of exon 1β that
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impair ARF function have been reported in a case of melanoma (Rizos et al., 2001).
Furthermore, the Arf promoter contains a CpG island, and ARF expression can
consequently be downregulated by promoter methylation (Robertson and Jones, 1998)
(Furonaka et al., 2004; Kominami et al., 2009; Konishi et al., 2002; Melendez et al.,
2000; Zemliakova et al., 2004; Zheng et al., 2000).

Arf transcription and translation
Arf transcription is upregulated in response to a host of oncogenic signals
including c-Myc, Ras, E2F-1. E1A, and v-Abl (Sherr, 2001) . Perhaps the two most wellstudied of these events, upregulation by c-Myc and Ras, were directly demonstrated in
vivo using a construct in which GFP is controlled by the Arf promoter (Zindy et al.,
2003). Given that oncogenic Ras plays an integral role in regulating cell growth, I will
focus my attention on the upregulation of Arf transcription by RasV12. Research into the
transcriptional regulation of Arf was initiated by searching the promoter for known
binding sites of transcription factors. The Arf promoter contains a binding site for the
DMP1 (cyclin D-binding Myb-like protein) transcription factor, namely a nonameric
DNA consensus sequence containing G-G/T-A cores (Hirai and Sherr, 1996). The DMP1
transcription factor was a likely candidate for Arf regulation given that it is known to
arrest mouse fibroblasts upon overexpression, and human DMP1 is frequently deleted in
myeloid leukemia (Bodner et al., 1999; Inoue and Sherr, 1998). In 1999, Inoue and
colleagues demonstrated that DMP1 binds and activates the Arf promoter. Moreover,
infection of wild-type MEFs with DMP1 induces ARF expression and a cell cycle arrest.
Importantly, in the absence of Arf, DMP1 overexpression had no effect on the cell cycle,
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indicating that DMP-1-induced arrest is dependent upon ARF (Inoue et al., 1999).
Subsequent studies have now shown that DMP1 is a key mediator of Ras-induced ARF
expression (Sreeramaneni et al., 2005). Until recently, ARF induction downstream
oncogenic Ras has largely been considered a transcriptionally-activated process.
However, Miceli and colleagues have demonstrated that RasV12 can induce ARF levels in
the absence of Dmp1. By signaling through the Ras/PI3K/TSC/mTOR pathway, this
induction in Dmp1-null cells occurs in the absence of enhanced ARF mRNA levels
(Miceli et al., 2011). Taken together, we now know that ARF is upregulated both
transcriptionally and translationally in response to oncogenic Ras to induce cell cycle
arrest.

ARF's structure, cellular location, and stabilization
The structure of ARF is important to consider when studying the protein's
localization, stabilization, and binding partners. Mouse ARF (p19ARF) contains 169 amino
acids, while human ARF (p14ARF) contains 132. Of this relatively small protein, nearly
20% of the residues are arginines, making ARF a highly basic protein. The basic nature
of ARF renders it highly insoluble and is likely the reason for its lack of structure.
Moreover, this property also renders ARF a very "sticky" protein, which makes it
difficult to discern which of its proposed binding partners are physiologically relevant. It
is likely that ARF requires consistent binding with another protein to bring its charge to a
more neutral pH in order to function in vivo (Ozenne et al.; Quelle et al., 1995; Sherr,
2006). In fact, owing to a nucleolar localization signal, ARF is typically found within
nucleoli bound in high molecular weight complexes with other proteins (Bertwistle et al.,
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2004) . In consideration of ubiquitination on lysine residues, it is interesting that mouse
ARF contains only one lysine (Lys26) while human ARF has none. ARF has a half-life
of about 6h, at which point it is degraded by ubiquitin-mediated proteasomal degradation.
However, studies have shown that the ubiquitin moiety is not added to the sole lysine in
mouse ARF as removal of that lysine still results in ARF's degradation. Instead, both
mouse and human ARF undergo N-terminal ubiquitination, which signals them for
destruction (Kuo et al., 2004).

1.3 p53-dependent ARF tumor suppression
ARF's classical role as a tumor suppressor is to activate p53. Given that p53 is the
most commonly mutated gene in human cancers, this is clearly a significant role of ARF.
p53 can induce both cell cycle arrest and trigger apoptosis in response to oncogenic
stimulation, DNA damage, and other cellular stressors. p53 exerts its functions by
transactivating target genes such as p21 and PUMA. Interestingly, another target of p53
transactivation is its own negative regulator, murine double minute 2 (MDM2, HDM2 in
humans) (Sherr and Weber, 2000). In the absence of cellular stress, p53 is bound by
MDM2. When MDM2 is bound to p53, p53 is physically unable to bind to target genes
and exert its function as a transcription factor (Momand et al., 1992; Oliner et al., 1993).
MDM2 also results in the nuclear export and eventual proteasomal degradation of p53
(Roth et al., 1998). Furthermore, MDM2 contains a RING domain, allowing it to act as
an E3 ubiquitin ligase and contribute to the ubiquitination of p53 (Haupt et al., 1997;
Honda et al., 1997; Kubbutat et al., 1997). The importance of the MDM2-p53 interaction
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is underscored by work demonstrating that mdm2-/- mice are embryonic lethal but can be
rescued by concomitant deletion of p53 (Jones et al., 1995).
When prompted by oncogenic signals such as RasV12 (Palmero et al., 1998) or
Myc overexpression (Zindy et al., 1998), ARF is upregulated. ARF then binds MDM2
via amino acids 1-14 and sequesters it in the nucleolus (Weber et al., 1999). The residues
important for the nucleolar localization of ARF are also within the first 37 residues of
exon 1β, and only these residues are necessary for fully functional ARF (I will later
discuss other roles of these residues). MDM2 likely also contributes to the nucleolar
localization of the complex as binding to ARF reveals MDM2's nucleolar localization
signal (Lohrum et al., 2000). Nucleolar localization prevents the binding of MDM2 to
p53 and the ability of MDM2 to shuttle between the nucleus and cytoplasm, thereby
impeding its ability to transport p53 to the cytoplasm for degradation (Tao and Levine,
1999). As is the case for Mdm2, Arf is a transcriptional target of p53, adding to the
negative feedback loop of p53 activation (Stott et al., 1998).
The importance of the ARF-MDM2 interaction is highlighted by studies
demonstrating that oncogenic insult is incapable of inducing p53 responses when ARF is
lost (Kamijo et al., 1997; Palmero et al., 1998). This suggests that ARF activity could be
mimicked by generating therapeutics to inhibit MDM2 in p53-positive cancers. A
synthetic class of molecules, called nutlins, was perhaps the most promising of MDM2
inhibitors, especially in the absence of ARF. They free p53 from MDM2's negative
regulation via binding a hydrophobic pocket of MDM2 that is critical for its interaction
with p53 (Vassilev et al., 2004). Initially, nutlins seemed as though they would be a
successful cancer therapy; upon nutlin treatment, p53-positive cancer cells either became
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senescent or underwent apoptosis. Nutlins also seemed promising in vivo when they were
successfully used to reduce tumor xenograft growth in mice (Vassilev et al., 2004).
Unfortunately, it became evident that nutlins would be too toxic due to prolonged p53
activity. The embryonic lethality of Mdm-2 mice supported this theory. When
considering that p53/Mdm2-null mice are viable, the Mdm2-null phenotype indicates that
unchecked p53 is deleterious during development (Jones et al., 1995; Montes de Oca
Luna et al., 1995). Furthermore, when p53 activity was conditionally upregulated in
Mdm2-null mice, the mice died within 1 week (Ringshausen et al., 2006). While this data
was unfortunate, it may have heightened the interest in identifying other, p53independent targets of the ARF tumor suppressor that could lead to additional therapeutic
targets in the absence of functional ARF.

1.4 p53-independent functions of ARF
It was not initially clear that ARF tumor suppression went beyond the scope of
p53. The first clue presented when mice were engineered to overexpress c-Myc. These
mice developed B-cell lymphomas with a mean survival of 6 months (Eischen et al.,
1999). It was previously known that oncogenic c-Myc activates the p53-MDM2-ARF
pathway in culture (Zindy et al., 1998). Therefore, the authors examined this pathway in
the mouse tumors. As may have been expected, a number of tumors either displayed p53
mutation, biallelic Arf loss, or MDM2 overexpression. Interestingly, some tumors also
presented either p53 mutations or biallelic Arf loss in conjunction with MDM2
overexpression (Eischen et al., 1999), which could be interpreted as MDM2 having p53independent tumor suppressive properties. However, it was also suggested that ARF may
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have p53-independent tumor suppressive functions based on this data. In 2000, Weber et
al. published their results of genetically engineered mice that were nullizygous for p53,
Mdm2, and Arf (known as triple knock-out, or TKO, mice). When compared to mice
lacking either p53 or Arf alone, mice lacking both p53 and Arf (with or without loss of
Mdm2) displayed a wider tumor spectrum and an increase in the number of primary
tumors (Weber et al., 2000). If ARF only exerted its tumor suppressive functions through
p53, we would have expected the TKO mice to display the same types of tumors as p53null mice. Furthermore, the results demonstrated that MDM2 antagonizes the p53independent tumor suppressive functions. Ectopically expressed ARF was unable to
arrest p53/Arf-null MEFs. However, ARF was able to rescue to these cells with
concomitant deletion of Mdm2. This phenomenon was explained by results showing that
an Arf mutant lacking amino acids 1-14, which are necessary for ARF's ability to bind
MDM2, are required for ARF to arrest TKO cells. In other words, ARF is unable to arrest
p53/Arf-null cells in the presence of antagonistic MDM2. Moreover, the amino terminal
14 amino acids of ARF are necessary for both its p53-dependent and -independent tumor
suppressive functions. In future sections, I will touch upon some of the reported ARFinteracting proteins that have emerged since the genetic evidence of p53-independent
ARF tumor suppression was presented.

Arf-interacting proteins beyond the realm of p53-dependent tumor suppression
In 2006, at least 30 proteins had been reported to interact with ARF (Sherr, 2006).
For a majority of the reported ARF-interacting partners, it is still too early to determine
whether their interaction is physiologically relevant, partially due to the promiscuity of
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ARF's binding. Interestingly, ARF is known to interact with another E3 ubiquitin ligase
aside from MDM2: ARF-BP1. ARF-BP1 contains a HECT domain and has been shown
to ubiquitinate p53. When bound to ARF, the ubiquitin ligase activity of ARF-BP1 is
inhibited (Chen et al., 2005). ARF is also known to interact with DP1, a binding partner
of the E2F family of transcription factors. The ARF-DP1 interaction inhibits the ability of
DP1 to activate the dhfr gene, which promotes cell cycle arrest (Datta et al., 2005). ARF
has also been shown to interact with MYC. Two studies were simultaneously published
that demonstrated the ability of ARF to block transcriptional activation by MYC in a p53independnet manner (Datta et al., 2004; Qi et al., 2004). One group further reported that
ARF exerts this function by sequestering MYC in the nucleolus (Datta et al., 2004).
UBC9 is another ARF-interacting protein (Rizos et al., 2005). UBC9 is a SUMO
conjugating enzyme that is of particular interest given recent reports demonstrating the
ability of ARF to promote protein sumoylation. Finally, I will highlight the ARF-NPM
interaction in forthcoming sections of this chapter as NPM is an important component of
my dissertation.

The relationship between ARF and NPM
One of the most well-studied and relevant ARF-interacting proteins is
nucleophosmin (NPM; also known as B23, numatrin, and NO38). NPM was first
identified as an ARF-interacting protein by four independent laboratories, all of which
reported slightly different stories on the physiological function of the interaction. Itahana
and colleagues reported that ARF-binding induces the ubiquitination and proteasomal
degradation of NPM (Itahana et al., 2003). This theory is somewhat tantalizing given
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that, at the time, ARF had published roles in inhibiting ribosomal RNA processing
(Sugimoto et al., 2003) while others had already published that NPM promotes this
process (Savkur and Olson, 1998). So, the authors suggested that their data provided the
mechanism by which ARF negatively regulates NPM's pro-growth properties (Itahana et
al., 2003). However, none of the other laboratories were able to reproduce the
ubiquitination and subsequent degradation of NPM by ARF. A few months later,
Bertwistle and colleagues reported that ARF interacts with NPM using the same aminoterminal 14 amino acids that are required for its interaction with MDM2. Furthermore,
they suggested that NPM's interaction with ARF compromises ARF's ability to prevent
ribosomal processing (Bertwistle et al., 2004). Brady and colleagues proposed a model in
which ARF binds NPM, and inhibits its shuttling from the nucleus to the cytoplasm,
resulting in cell cycle arrest. Their data went on to verify that amino acids 1-14 of ARF
were necessary for binding NPM as an ARF mutant lacking this domain (ARF ∆1-14) did
not coimmunoprecipitate NPM (Brady et al., 2004). Furthermore, the ARF-NPM is
MDM-2-sensitive as reintroduction of MDM2 releases NPM from ARF (Brady et al.,
2004). The final group again verified that ARF's interaction with NPM was dependent
upon its first 14 amino acids. However, they suggest that the interaction is important to
prevent ARF from exerting its p53-dependent tumor suppressive functions (Korgaonkar
et al., 2005). This data is in direct contrast to the aforementioned results that
demonstrated a preferential binding of ARF to MDM2. If we can gather one thing from
the four individual reports, it is that NPM is a bona fide interaction partner of ARF.
Given this interaction and that my work has centered on the p53-independent growth
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regulatory properties of ARF, I will now focus on what we have since learned about
NPM in promoting cell growth.

NPM and cell growth
NPM is a highly conserved 37kDa phosphoprotein. Although originally described
as a nucleolar resident, NPM is capable of shuttling between the nucleoplasm and
cytoplasm (Kang et al., 1974; Kang et al., 1975), a function that is important for ribosome
export as will be discussed later. NPM is highly expressed under basal conditions, and its
expression is exacerbated upon mitogenic stimulation. Work from our lab has shown that
oncogenic Ras signals through mTOR to upregulate the translation of NPM (Pelletier et
al., 2007). Furthermore, the upregulation of NPM protein was independent of changes at
the mRNA level (Pelletier et al., 2007). Olanich and colleagues have since shown that the
3'-UTR of NPM is sufficient to mediation upregulated translation through mTOR
(Olanich et al.). Both studies have additionally demonstrated that the translational
upregulation of NPM via mTOR results in higher rates of protein synthesis and enhanced
proliferation in the absence of p53 (Olanich et al.; Pelletier et al., 2007). Furthermore,
NPM is progrowth as its overexpression has been shown to increase cell size in Arf -/MEFs and transform p53-/- MEFs in soft agar (Brady et al., 2009). Npm1-null mouse
models have demonstrated the importance of NPM in the maintenance of cell growth and
proliferation as they are embryonic lethal (Grisendi et al., 2005). Furthermore, in highly
proliferative and tumorigenic cells, NPM expression is elevated compared to normal
cells. These data were some of the first to suggest a role for NPM in regulating cell
growth and proliferation (Borer et al., 1989; Yun et al., 2003). Since then, multiple
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groups have reported that NPM is overexpressed in a variety of human tumors (Bernard
et al., 2003; Brady et al., 2009; Nozawa et al., 1996; Shields et al., 1997; Skaar et al.,
1998; Subong et al., 1999; Tanaka et al., 1992; Tsui et al., 2004). On the other hand,
NPM expression is known to be reduced in a number of human cancers as a result of
either gene deletion or genetic alterations. Considering this data alone, it is not surprising
that NPM has been ascribed both oncogenic and tumor suppressive roles (Grisendi et al.,
2006). In future sections, I will largely focus on oncogenic NPM as it is directly related to
NPM's role in ribosome biogenesis and cell growth.
NPM's nucleocytoplasmic shuttling is CRM-1 dependent and required for the
export of ribosomal components (Borer et al., 1989; Maggi et al., 2008; Yu et al., 2006).
Ribosomal protein L5 (rpL5) is a chaperone for the 5S rRNA and the first reported
component of the ribosomal machinery to be exported by NPM (Yu et al., 2006). In this
study, the authors created a shuttling-deficient mutant of NPM, in which two leucines
within the nuclear export sequence of NPM were mutated to alanines. The mutation
completely abrogated the nucleocytoplasmic shuttling ability of NPM, blocked the export
of both rpL5 and 5S rRNA, and ultimately resulted in cell cycle arrest (Yu et al., 2006).
In an effort to determine if NPM interacted with other components of the ribosome
machinery, Maggi et al. generated a polyclonal NPM affinity column. Their efforts
resulted in a list of 10 components of the 40S and 60S subunits and an additional 9
proteins known to be important in translation (Maggi et al., 2008). NPM was also
demonstrated to be required for protein synthesis by use of the shuttling-deficient mutant
as well as siRNA-mediated kncokdown of NPM (Maggi et al., 2008). Furthermore, the
importance of NPM's role in shuttling ribosomal components out into the cytoplasm is
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highlighted by electron micrographs of the nuclear/cytosol boundary from Npm hy/hy
(hypomorphic NPM alleles that express nearly undectectable levels of NPM) (Grisendi et
al., 2005) MEFs, where one can clearly see the accumulation of ribosomes along the
inside perimeter of the nucleus (Maggi et al., 2008). NPM mutations in acute myeloid
leukaemia underscore the importance of NPM's shuttling function (Falini et al., 2005).
The NPM mutation causes a frameshift that results in an additional NES and concomitant
loss of NPM's nucleolar localization motif (Bolli et al., 2007; Falini et al., 2006). These
changes result in the cytoplasmic localization of NPM and thus, this mutant has been
designated NPM cytoplasmic positive or NPMc+. Cheng and colleagues subsequently
demonstrated that NPMc+ is an oncogene in that it can transform mouse embryonic
fibroblasts in cooperation with E1A in soft agar assays (Cheng et al., 2007). Cheng et al.
went on to show that oncogneic potential of NPMc+ was relevant in vivo by creating
transgenic mice that express the NPMc+ mutant. The mutant mice developed
myeloproliferation in bone marrow and spleen whereas expression of wild-type NPM did
not result in disease (Cheng et al.). This NPM mutation also brings forth an important
aspect of the ARF-NPM interaction. NPM has been demonstrated to maintain the
stability of ARF within the nucleolus (Colombo et al., 2005; Colombo et al., 2006;
Korgaonkar et al., 2005). In fact, the NPMc+ mutant takes ARF along as it aberrantly
shuttles to the cytoplasm, which reduces the stability of ARF and interferes with both
p53-dependent and p53-independnet tumor suppressive functions of ARF (Colombo et
al., 2006; den Besten et al., 2005). Given the importance of the ARF-NPM interaction in
cell growth, I will outline future experiments in Chapter 4 to determine the role of NPM
in post-mitotic cells.
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1.5 What is basal ARF doing?
While ARF is primarily recognized as a protein upregulated in the face of
oncogenic distress, there has been recent data suggesting important roles for basal ARF.
It is becoming increasingly clearer that even thought ARF is nearly undetectable in many
cells lines, it plays an integral role based on studies analyzing the effects of its loss. This
emerging field is of particular importance to my project as we have studied the effects of
basal Arf loss during osteoclastogenesis. In this section, I will cover the known roles of
basal ARF in regulating mouse eye development, male germ cell production, and protein
synthesis. In the following section, I will discuss what we know about the role of basal
ARF in osteoblasts.

The role of ARF in mouse eye development
Initially, Arf -/-mice seemed developmentally normal despite the fact that their
eyes were slightly smaller compared to the eyes of wild-type mice (Kamijo et al., 1999;
Kamijo et al., 1997; McKeller et al., 2002). Upon closer examination, McKeller and
colleagues noticed that Arf -/- mice had a funnel-shapped mass of cells in the vitreous of
their eyes just behind the lens. During postnatal day 1 through 10, this mass of cells is
present and at least some of the cells are dividing. Although the authors did not notice an
increase in the overall size of the cell mass as the mice aged, they did record its presence
through 8 months of age. Notably, this retrolental mass of cells was not present in wildtype or Arf +/- mice (McKeller et al., 2002). Wild-type mice are born with elements of the
hyaloid vascular system (HVS), including endothelial cells, perivascular cells forming the
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hyaloid artery, and several other types of perivascular cells that form the structures of the
vasa hyaloidea propria (VHP), the tunica vasculosa lentis, which surrounds the lens, and
the pupillary membrane. Normally, the HVS will regress by postnatal day 14 (Ito and
Yoshioka, 1999). Although the HVS was still present in Arf -/- P10 mice, the authors did
not detect any cellular components of the HVS by postnatal day 10 in wild-type mice
(McKeller et al., 2002). Expression of ARF mRNA was examined in gross sections of the
eye and found primarily in the vitreous. Given the localization of ARF and that most of
the retrolental mass was centered within the region of the VHP, the authors suggested
that ARF might regulate VHP regression (Ito and Yoshioka, 1999). Regression of the
HVS, which includes the VHP, is important for normal eye development; failed
regression results in a human eye disease known as persistent hyperplastic primary
vitreous or PHPV and results in microphthalmia (abnormally small eyes) (Goldberg,
1997; Haddad et al., 1978). Arf -/-mice were examined for two primary characteristics of
PHPV: retrolental fibrovascular tissue lining the inner neuroretina resulting in retinal
abnormalities and retrolental fibrovascular tissue that adheres to the posterior of the lens
(Haddad et al., 1978). For the most part, the neuroretina and lens of Arf -/-mice appeared
normal through P10. However, beginning at P14, Arf -/-mice displayed both defects in the
neurorentina and the lens, which ultimately results in blindness (McKeller et al., 2002).
Importantly, the characteristics of PHPV were not observed in p53 -/- mice, indicating that
the role of ARF in hyaloid vascular regression is independent of p53 (McKeller et al.,
2002). To better understand the molecular mechanisms by which ARF regulates HVS
regression, Silva and colleagues examined Arf Gfp/+ mice. In these mice, one allele of Arf
is replaced by Gfp, allowing for a more sensitive means of detecting tissues and cells in
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which Arf expression occurs in vivo (Zindy et al., 2003). Results showed that ARF was
expressed in the vitreal perivascular structures between embryonic day 11.5 (E11.5) and
E18.5. Postnatally, GFP-positive cells were detected in mural cells expressing Pdgfrβ
(Silva et al., 2005). In normal development, endolthelial cells within the vitreal HVS
secrete PDGF-β, which then binds to cognate receptors on pericyte-like mural cells to
support the developing lens (Gerhardt and Betsholtz, 2003; Ito and Yoshioka, 1999;
Lindahl et al., 1997; Zhu et al., 1999). We now know that ARF regulates the proliferation
of pericyte-like mural cells that express the PDGF-β receptor; and without ARF, these
cells abnormally proliferation, resulting in lack of complete HVS regression, and
ultimately, blindness (Gromley et al., 2009; Silva et al., 2005).

The role of ARF in male germ cell development
In addition to ARF expression within the eye, the Arf Gfp/+ mice also revealed
expression of ARF in one other normal cell: male spermatogonia (Zindy et al., 2003).
Using a more sensitive system that is capable of detecting transient expression of ARF,
Gromey and colleagues confirmed ARF's presence during male germ cell development
(Gromley et al., 2009). In mice, spermatogenesis occurs within the first month of life.
Spermatogonia are cells that line the basement membrane of each seminiferous tubule;
these are the cells that express ARF (Gromley et al., 2009). Spermatogonia will enter
meiosis I, moving toward the lumen of the tubule as they progress, during P7-P10.
During this stage the cells are known as spermatocytes and undergo homologous
recombination between homologous chromosomes. By P18, meiosis I is complete and the
spermatocytes move directly into meiosis II to form haploid cells. Spermatogenesis is
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complete once the spermatocytes differentiate into mature spermatozoa around P35
(Cole et al.) Arf -/-mice have reduced sperm number compared to that in wild-type mice
due to an increase in apoptosis during germ cell development (Churchman et al.; Cole et
al.). Notably, there was no increase in the proliferation of spermatogonia during germ cell
development upon Arf loss (Churchman et al.). While the apoptosis of these cells is
dependent upon p53, the functions of ARF that regulate apoptosis are independent of
p53. Cells void of Arf display increased levels of phosphorylated histone H2AX
(Churchman et al.). H2AX is normally phosphorylated at the leptene stage of meiosis, but
disappears by early pachytene upon synapsis of homologous chromosomes (Inagaki et
al.; Mahadevaiah et al., 2001). Thus far, the data suggest that persistent phosphorylated
H2AX signals cells for apoptosis, although this has not been convincingly demonstrated.
Importantly, deletion of p53 was unable to rescue the defect in H2AX phosphorylation
(Churchman et al.). Taken together, this role of ARF in male germ cell development is
counterintuitive given what we already know about the ARF-p53 interaction; ARF
actually prevents p53 from inducing apoptosis in primary spermatocytes (Churchman et
al.).

Basal ARF regulates nucleolar structure and function
Given the nucleolar localization of ARF and its interaction with NPM, Apicelli
and colleagues examined the role of basal ARF in maintaining nucleolar structure and
limiting protein synthesis (Apicelli et al., 2008). Arf loss resulted in an increase in both
the number and size of AgNORs in mouse embryonic fibroblasts (MEFs) (Apicelli et al.,
2008). AgNORs highlight argyrophilic proteins that surround nucleoli. An increased
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AgNOR index has classically been associated with poor prognoses in cancer (Pich et al.,
2000) and, thus, this data suggested that ARF maintains the structure and likely function
of proteins within nucleoli. This data was corroborated by in situ AgNOR staining on
tissues from Arf -/- mice. Both intestine and liver tissue exhibited an increase in total
AgNOR area in the absence of Arf (Apicelli et al., 2008). In low-passage MEFs, Arf loss
also enhances protein synthesis as assessed by 35S-methionine incorporation, resulting in
a increase in both protein content and cell volume (Apicelli et al., 2008). Importantly,
enhanced protein synthesis in these cells was shown to be independent of proliferation as
the total cell number did not increase over 7 days. Again, the increases in protein
synthesis upon Arf loss was supported by in vivo results demonstrating that
Arf loss in liver tissue also causes an increase in protein synthesis by 35S-methionine
incorporation (Apicelli et al., 2008). To determine if enhanced protein synthesis could, at
least partially, be attributed to an increase in protein output, Apicelli and colleagues
isolated cytosolic fractions from WT and Arf -/- MEFs, ran the fractions over a sucrose
gradient, and monitored the RNA absorption. An increase in ribosome output upon Arf
loss was observed in vitro and supported by identical experiments done using liver tissue
from Arf -/-mice (Apicelli et al., 2008). Together, this data demonstrates that basal Arf loss
profoundly enhances cell growth in mitotic cells over time. To determine if acute Arf loss
would have the same effects on mitotic cell growth, Apicelli and colleagues knocked
down ARF by lentiviral transduction with an shRNA against exon1β. Again, the authors
observed an increase in the number of AgNORs upon Arf loss as well as an increase in
total AgNOR area (Apicelli et al., 2008). In fact, these changes were even more
pronounced than those observed with chronic loss of Arf, which suggests that cells with

24

chronic Arf loss may have a means in which to compensate and control nucleolar
morphology. Acute Arf loss also resulted in enhanced protein synthesis and ribosome
output (Apicelli et al., 2008). Taking a step back in the production of ribosomes, the
authors examined the transcription of rDNA and the processing of rRNA given that
previous studies had demonstrated a role for ARF in both of these processes (Ayrault et
al., 2006; Ayrault et al., 2004; Qi et al., 2004; Sugimoto et al., 2003). Furthermore, it is
conceivable that ARF could simultaneously dampen multiple aspects of ribosome
biogenesis as serial immunoprecipitation experiments have shown that only some of the
ARF protein in the cell is bound to NPM (Apicelli et al., 2008). Loss of Arf resulted in a
significant increase in newly transcribed 47S transcripts as demonstrated by quantitative
RT-PCR, a result that was independent of shRNA-mediated knockdown of Myc. The
data further suggests that Arf loss results in enhanced processing of the newly transcribed
47S rRNA, which supports previous findings (Apicelli et al., 2008; Sugimoto et al.,
2003). Specifically, in accordance with previously published data from Sugimoto and
colleagues, the data suggested that ARF impedes processing of the 47S rRNA into the
32S rRNA intermediate (Apicelli et al., 2008; Sugimoto et al., 2003). The final step of
ribosome biogenesis is the export of the ribosomal subunits. By radioactively labeling the
rRNA subunits with 3H-methyl methionine, it was demonstrated that Arf -/- MEFs export
ribosomal subunits into the cytoplasm at a faster rate than that observed in wild-type cells
(Apicelli et al., 2008). This result is in accordance with previously published data
showing that ARF interacts with NPM, which is known to be important for shuttling
ribosomes from the nucleus to the cytoplasm (Maggi et al., 2008; Pelletier et al., 2007;
Yu et al., 2006). Importantly, Apicelli and colleagues made the point that the enhanced
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export of ribosomes is not solely reflective of the fact that Arf loss enhances the
transcription and processing of rRNA; instead, Arf loss amplifies each of the three steps
in ribosomal biogenesis: transcription, processing, and export (Apicelli et al., 2008).
Finally, the authors used shRNA-mediated knockdown of NPM to determine if the
enhanced protein synthesis observed in Arf -/- MEFs was due to unrestrained NPM
activity. Upon testing the three steps in ribosomal biogenesis, it was determined that
unrestrained NPM activity could explain the enhanced export of ribosomal subunits upon
Arf loss. Furthermore, knockdown of NPM in Arf -/- MEFs brought overall rates of protein
synthesis back to levels observed in wild-type cells (Apicelli et al., 2008). Taken
together, the work from Apicelli and colleagues, in association with other groups,
suggests that basal ARF limits the amount of protein synthesis in mitotic cells by
impeding multiple steps of ribosome biogenesis (Figure 1.3).

1.6 Modeling proliferation-independent growth
Given the aforementioned role of basal ARF in regulating ribosome biogenesis
and protein synthesis, Apicelli and colleagues initiated the study of ARF in osteoclasts.
The goal of this work was to demonstrate the physiological relevance of ARF's growth
control. The osteoclast is a unique model in which to focus on cell growth regulation
because they require protein synthesis to differentiate and be fully functional, and they
are post-mitotic in their mature state. Before discussing the results of this initial study, I
would first like to review osteoclast differentiation and the features of mature osteoclasts.
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Osteoclast differentiation
Osteoclasts are the bone resorbing cells of the body. They are essential for normal
bone turnover or remodeling as evidenced by skeletal diseases such as osteoporosis that
occur when they dysfunction. Skeletal diseases may also result due to enhanced or
delayed differentiation of osteoclasts. Osteoclasts are derived from the
monocyte/macrophage family in the hematopoietic lineage (Coccia et al., 1980). The use
of animal models has revealed important factors during osteoclastogenesis (Figure 1.4).
The earliest known transcription factor important for osteoclastogenesis is PU.1. In the
absence of PU.1, mice do not generate bone marrow macrophages resulting in
osteopetrosis (Henkel et al., 1996; Scott et al., 1994; Tondravi et al., 1997). PU.1 is
important for the transcription of lineage-specific cytokine receptors including the
macrophage colony-stimulating factor (M-CSF) receptor, c-fms (Singh et al., 1999) and
the receptor activator of NF-κB (RANK) (Kwon et al., 2005). In conjunction with other
transcription factors, PU.1 also induces the transcription of two of the most wellcharacterized OC-specific target genes: Cathepsin K and tartrate-resistant acid
phosphatase (TRAP) (Matsumoto et al., 2004; Partington et al., 2004). Clearly, PU.1 is
important throughout osteoclast development, which explains why its levels nearly triple
during osteoclastogenesis (Tondravi et al., 1997). Another early transcription factor that
collaborates with PU.1 is MITF, which is encoded by the microphthalmia (mi) locus.
Loss of Mitf results in osteopetrosis as a result of inadequate osteoclasts (Hershey and
Fisher, 2004). This is due to the fact that MITF is necessary for the transcription of
essential osteoclast genes including TRAP and carbonic anhydrase II (CAII) (Luchin et
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al., 2000; Luchin et al., 2001). However, Mitf-null mice do form macrophages, placing
MITF downstream of PU.1 in osteoclastogenesis (Thesingh and Scherft, 1985).
M-CSF, which is expressed by osteoblasts, plays a pivitol role in
osteoclastogenesis. M-CSF-deficient (op/op) mice are osteopetrotic due to insufficient
osteoclasts (Yoshida et al., 1990). M-CSF promotes differentiation, the proliferation and
survival of precursors, and cytoskeletal reorganization (Insogna et al., 1997; Sherr et al.,
1988; Tanaka et al., 1993; Woo et al., 2002). In order to carry out its functions, M-CSF
must bind to its reception, c-Fms. Thus, loss of c-fms also results in osteopetrosis in mice
as a result of an osteoclast deficiency (Dai et al., 2002). Upon binding to c-Fms, M-CSF
exerts a number of downstream intracellular events including the induction of genes
necessary for the cell to respond to interleukins and RANKL (Cappellen et al., 2002). In
particular, M-CSF upregulates the expression of RANK (Cappellen et al., 2002), which is
the receptor for RANKL and the only other cytokine that , together with M-CSF, is
required for osteoclast differentiation in vitro (Lacey et al., 1998; Yao et al., 2002;
Yasuda et al., 1998). Notably, upon binding its ligand, c-Fms autophosphorylates, which
leads to the recruitment of adaptor molecules. One of the most well-studied and important
of these adaptor proteins is c-Src, which is discussed further in this section (Feng et al.,
2002).
Perhaps the most essential component of osteoclastogenesis is RANKL, also
known as TNF-related activation-induced cytokine (TRANCE), osteoprotegrin ligand
(OPGL), or OC differentiation factor (ODF). As one of the alternative names suggest,
RANKL is a member of the tumor necrosis factor (TNF) family. A major discovery in
delineating the molecular events promoting osteoclastogenesis came when Suda and
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colleagues demonstrated that osteoclast precursors must come in contact with osteoblasts
(or their precursors) for osteoclastogenesis to ensue (Udagawa et al., 1990). This finding
paved the way for the understanding that RANKL is produced by osteoblasts and then
binds to RANK on the surface of macrophages to induce osteoclastogenesis. The
importance of this interaction is underscored by the fact that knockout mice of either the
ligand or the receptor do not make osteoclasts and are severely osteopetrotic (Dougall et
al., 1999; Lacey et al., 1998; Li et al., 2000). RANK activation recruits adaptor molecules
of the TNF receptor-associated family (TRAFs) (Darnay et al., 1999; Galibert et al.,
1998). TRAFs relay the RANKL signal to activate all three MAP kinase pathways,
including ERK, p38, and JNK, as well as PI-3K and NF-κB (Del Fattore et al., 2008).
Finally, it is important to note that in addition to advancing osteoclastogenesis, RANKL
both induces osteoclast resorption and promotes osteoclast survival (Burgess et al., 1999).
One of the most well-characterized and important downstream effectors of RANKL is the
transcription factor, nuclear factor of activated T-cells cytoplasmic 1 (NFATc1). NFATc1
belongs to a family of NFAT transcription factors and is the major NFAT found in
osteoclasts (Day et al., 2005). Osteoclastogenesis is halted in the absence of NFATc1
(Takayanagi et al., 2002). More importantly, overexpression of NFATc1 can rescue
RANKL deficiency, indicating that it is the primary transcription factor downstream of
RANKL that is responsible for osteoclast differentiation (Takayanagi et al., 2002). In
cooperation with other transcription factors, namely Fos and Jun proteins, NFATc1
induces genes critical for osteoclast function, such as the calcitonin receptor, cathepsin K,
and β3 integrin (Crotti et al., 2005; Ikeda et al., 2004; Kim et al., 2005a; Kim et al.,
2005b; Matsumoto et al., 2004).
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As previously mentioned, NF-κB is one of the primary pathways activated by
RANKL. NF-κB is family of five transcription factors that includes p50 (NF-κB1), p52
(NF-κB2), p65 (RelA), c-Rel, and RelB. The Rel domains in each of these proteins
allows for dimerization and DNA binding (Thanos and Maniatis, 1995). In the absence of
RANKL, NF-κB is bound by IκB proteins, keeping it inactive in the cytosol. Upon
RANKL activation, IκB is phosphorylated by IKK (IκB kinase), leading to its
degradation. NF-κB is then free to translocate to the nucleus and promote the
transcription of OC-specific genes (Thanos and Maniatis, 1995). Without the NF-κB
pathway, mice are osteopetrotic as a result of insufficient osteoclastogenesis (Abu-Amer
et al., 2001).
In corroboration with NF-κB, AP-1 induces the transcription of genes important
for osteoclastogenesis. There are two primary components of AP-1: Fos and Jun proteins
(Wagner and Eferl, 2005). RANKL promotes the induction of c-Fos (David et al., 2002).
Mice lacking c-Fos do not produce osteoclasts and are therefore osteopetrotic
(Grigoriadis et al., 1994; Johnson et al., 1992; Wang et al., 1992). One of the most
notable targets of Fos transcription is NFATc1. In fact, overexpression of NFATc1 can
rescue loss of Fos (Matsuo et al., 2004). Loss of c-Jun activity also results in deficient
osteoclastogenesis and resultant osteopetrosis (Ikeda et al., 2004). As with c-Fos,
RANKL stimulation results in the activation of c-Jun (Kim et al., 1999). In summary,
RANKL induces the activation of various downstream transcription factors including
NFATc1, NF-κB, and AP-1, and results in a cell committed to the osteoclast lineage. In
the next section, I will discuss the final steps in becoming a fully functional osteoclast.
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The making of a fully functional osteoclast
Once committed to the osteoclast lineage, the initial step in bone resorption is
binding the bone. The formation of a tight seal to bone requires integrins. Integrins such
as αvβ3 bind actin complexes within the osteoclast and proteins in the bone matrix
containing RDG (ArgGlyAsp) motifs (Aubin, 1992). Itgb3-/- (β3 integrin-null) mice have
an enhanced number of osteoclasts. However, the osteoclasts are unable to resorb bone,
resulting in increased bone mass by 4 months of age. Upon closer examination,
researchers found that the osteoclasts in these mice do not adhere to bone, have an
abnormal cytoskeletal arrangement, and do not form a ruffled border, all of which are
important for osteoclast function (McHugh et al., 2000). Src is also an important mediator
of these functions, namely cytoskeletal rearrangements and ruffled border formation.
Similar to Itgb3-/- mice, Src-/- mice have adequate numbers of osteoclasts (Soriano et al.,
1991). However, they have faulty bone resorption due to defective osteoclast spreading
and a reduction in the number of H+-ATPases at the resorptive front (Boyce et al., 1992).
In terms of osteoclast spreading, Src is believed to be important for transmitting signals
emanating from the bone matrix and mediated through αvβ3 to the cytoskeleton
(Teitelbaum and Ross, 2003). Cytoskeletal rearrangements are important for the vesicular
trafficking of bone resorptive components to the cell-bone membrane interface, known as
the ruffled border. The ruffling of the membrane is formed at the site of active resorption
as a result of the insertion of many H+-ATPases. Hence, without Src to mediate the
cytoskeleton and allow for trafficking of the proton pumps, there are fewer H+-ATPases
at the resorptive front and a ruffled border is not formed (Boyce et al., 1992).
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The bone matrix is composed of both a mineralized component and an organic
component, both of which are resorbed by the osteoclast (Blair, 1998). Importantly, the
resorptive lacunae is the area of active resorption and can be locally acidified without
affecting the pH of the surrounding area due to the tight seal formed by the
aforementioned integrin and actin contacts with the bone. The importance of acidification
in bone resorption explains the need for trafficking of many H+-ATPases to the ruffled
border (i.e. the part of the osteoclast membrane contact the resorptive lacunae). A
lowered pH (around 4.5) is sufficient to dissolve the mineralized component of the bone.
Furthermore, as verified by mouse models, acidification of the resorption lacunae is also
necessary for the activation of bone-degrading enzymes. In mice lacking a necessary
component of the proton pump, enzyme activity was diminished and resorption was
reduced (Scimeca et al., 2000). While the presence of a fully functioning proton pump is
critical to osteoclast function, it is meaningless without an adequate supply of protons
from within the cell. To generate protons, enzymatic carbonic anhydrase II (CA-II)
converts H2O and CO2 into H2CO3. The H2CO3 then dissociates to form HCO3- and the
necessary protons (Sly and Hu, 1995). Thus, CA-II is critical for osteoclast function and
without it, mice have a trabecular bone volume that is 50% greater than that in wild-types
(Margolis et al., 2008). Importantly, the HCO3- ions are exchanged on the cell membrane
for Cl- ions; this occurs on a portion of the membrane outside of the sealing zone. The Clions are important because they are subsequently exported into the resorption lacunae as
protons are being pumped out, which allows the intracellular pH to remain neutral
(Kornak et al., 2001; Schlesinger et al., 1997).
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Cathepsin K is arguably the most important enzyme in the degradation of the
organic components of the bone. It is localized within lysosome of osteoclasts and
secreted in the resorption lacuae. Humans lacking Cathepsin K have pycnodysostosis,
which is characterized by short stature, dense bones, and other bone malformations (Gelb
et al., 1996). These defects are recapitulated in CtsK-/- mice, which are also osteopetrotic
(Saftig et al., 1998). While the mice have normal numbers of osteoclasts, they are unable
to properly resorb bone (Nishi et al., 1999; Saftig et al., 1998). Cathepsin K is further
discussed in Chapter 2. Matrix metalloproteinases (MMPs) are also important to the
functioning osteoclast. They are known to cleave cytokines and growth factors in
addition to the organic matrix of bone (Krane and Inada, 2008). MMP13-null mice
exhibit increase bone density as a result of decreased osteoclast function (Kosaki et al.,
2007; Stickens et al., 2004). Additionly, both MMP13 and MMP9 have been shown to
regulate osteoclast recruitment and invasion, which may highlight the more important
roles of MMPs in osteoclast function (Inada et al., 2004; Vu et al., 1998). One final
enzyme that is a canonical marker of osteoclast function is tartrate-resistant acid
phosphatase (TRAP). TRAP is expressed in both macrophages and osteoclasts and has
long been used as a histochemical marker for osteoclasts (Burstone, 1959; Minkin, 1982).
TRAP is a secreted protein, although its exact function is somewhat unclear (Kirstein et
al., 2006). The most well-characterized function of TRAP is the hydrolysis of the
phosphoprotein, osteopontin (OPN) (Suter et al., 2001). OPN is a protein important for
osteoclast attachment to the bone. It has been proposed that TRAP dephosphorylates
OPN, which would then allow the osteoclast to migrate to another area for resorption
(Ek-Rylander et al., 1994). The importance of TRAP to osteoclast function is emphasized
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by the phenotype of mice lacking TRAP. TRAP-/- mice display a myriad of skeletal
malformations including mild osteopetrosis and increased bone density (Hayman et al.,
1996).

The role of Arf in bone
Finally, I would like to discuss the known roles of ARF in bone turnover. First,
given the physiological communication between osteoclasts and osteoblasts, it is
important to consider the role of ARF in osteoblasts.

The role of Arf in osteoblasts
Under osteogenic conditions, bone marrow stromal cells can be differentiated into
osteoblasts (OBs). Arf -/- stromal cells exhibit enhanced osteoblastogenesis compared to
wild-type counterparts when assessed by alkaline phosphatase (ALP) expression and
mineralization in vitro (Rauch et al.). Data also suggests that ARF regulation of
osteoblastogenesis is relevant in vivo. Long bones taken from 8-week-old Arf -/- displayed
elevated levels of OB differentiation markers compared to bones from wild-type mice.
This is correlated to increased bone formation as quantified by double calcein labeling as
well as elevated serum osteocalcin levels, which is a biomarker of mature OBs. Finally,
when comparing Arf -/- mice to wild-types, the authors observed an overall increase in
trabecular bone volume in conjunction with higher levels of bone mineral density,
trabecular number, and trabecular thickness as assessed by microCT (Rauch et al.).
Importantly, Hurchla and colleagues subsequently determined that enhanced
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osteoblastogenesis was at least partially due to enhanced proliferation of osteoblast
precursors upon Arf loss (unpublished communicated data).

Initial study of ARF in osteoclasts
As previously mentioned, the study of ARF in osteoclasts was initiated to
determine if the changes in protein synthesis upon loss of basal Arf were physiologically
relevant; in other words, would loss of Arf have an impact on the function of a cell with
obvious protein synthesis demands? Apicelli and colleagues first differentiated bone
marrow-derived macrophages from wild-type or Arf -/- mice in the presence of M-CSF
and RANKL. After three days in the osteoclastogenic media, they observed an increase in
the number of TRAP-positive (via staining with a TRAP substrate) multinucleated
osteoclasts in the absence of Arf (Apicelli et al., 2008). Arf loss also appears to enhance
the activity of mature osteoclasts. Upon plating equal numbers of TRAP-positive cells,
day 4 WT osteoclasts were compared to day 3 Arf -/- osteoclasts. Arf -/- osteoclasts had
nearly twice as much TRAP activity as WT osteoclasts as assessed by the addition of a
TRAP substrate (Apicelli et al., 2008). Furthermore, the authors assessed in vivo activity
of osteoclasts by serum TRAP activity. Arf -/- mice exhibited a significant increase in
serum TRAP activity relative to that observed in WT mice (Apicelli et al., 2008).
Importantly, BrdU incorporation experiments done using bone marrow macrophages in
vitro did not show a difference in proliferation upon Arf loss (Apicelli et al., 2008).
Together, this suggests that Arf loss enhanced osteoclast activity both in vitro and in vivo
and is independent of precursor proliferation (Figure 1.5). Finally, Apicelli and
colleagues demonstrated that loss of NPM by shRNA-mediated knockdown abrogates the
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enhanced osteoclastogenesis observed in Arf -/- cells (Apicelli et al., 2008). This data
suggests that ARF may be regulating osteoclastogenesis by impeding protein synthesis
(Figure 1.6).

1.6 Dissertation objectives
At the onset of this project, the ARF field was well aware that ARF levels are
induced in the presence of oncogenic stress to impede cell proliferation. The mechanism
of ARF tumor suppression has long been appreciated to include the sequestration of
MDM2 and thus, the activation of p53 activity. As demonstrated by the myriad of ARFinteracting targets aside from MDM2, it is clear that the ARF field has embraced the idea
of p53-independent ARF tumor suppression. Our lab has largely focused on the ability of
ARF to bind NPM and prohibit its nucleocytoplasmic shuttling, which certainly
contributes to decreased protein synthesis and cell growth. Given that cell growth is
intimately tied to the progression of the cell cycle, one of the primary questions of my
project was to determine if ARF regulates protein synthesis in a proliferation-independent
context. Furthermore, the ARF field has more recently focused on the function of basal
ARF. While the importance of enhanced ARF levels upon oncogenic stress is becoming
overwhelmingly clear, the significance of basal ARF is still in its infancy. There have
been minimal reports demonstrating a physiologically-relevant function of basal ARF
including the role of ARF in eye development, male germ cell development, osteoblast
activity. Our lab has most recently demonstrated a role for basal ARF in the maintenance
of nucleolar structure and function, which ultimately results in the regulation of protein
synthesis. These studies were done using mitotic cells. Therefore, we were inclined to
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study this function of ARF in a post-mitotic setting such that we could satisfy the first
goal of the project: does ARF regulate protein synthesis in a proliferation-independent
context? Importantly, we also wanted to choose a physiologically-relevant setting. We
choose the osteoclasts as a model given our preliminary published results and realizing
that osteoclasts have a demand for protein synthesis to properly function. Using this
system, we additionally satisfied a second goal of the project: to determine if basal ARF
regulation of protein synthesis is physiologically-relevant. Finally, we anticipated that the
completion of this project would allow the field to better understand the teleological
function of ARF, namely that ARF is first and foremost a regulator of protein production.
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Figure 1.1
Ribosome production. Ribosome production begins with the transcription of the
ribosomal DNA. The transcript is then modified, a process that is guided by small
nucleolar RNAs (snoRNAs). RNases cleave the transcript to produce the mature 18S,
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5.8S, and 28S rRNAs. These rRNAs further associate with ribosomal proteins to
ultimately form the small (40S) and large (60S) ribosomal subunits. The subunits are then
exported to the cytoplasm for protein synthesis. Adapted from Ruggero and Pandolfi,
2003.
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Figure 1.2
Organization of the INK4a/Arf locus. INK4a and ARF share exons 2 and 3. Exon1α is
unique to INK4a, while exon1β is unique to ARF. The first exons of INK4a and ARF
splice into exon 2 in alternative reading frames such that the light green portion encodes
for INK4a and the dark green portion encodes for ARF. Adapted from Saporita et al.
2007.
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Figure 1.3
Basal ARF is known to regulate multiple steps in the control of protein synthesis. Arf
loss results in increased transcription of ribosomal DNA (rDNA), suggesting that ARF
impedes rDNA transcription in the nucleolus. Within the nucleolus, ARF also inhibits the
processing of the newly transcribed 47S rRNA into the mature 28S, 5.8S, and 18S
ribosomal subunits. In the nucleus, ARF impedes NPM-mediated export of mature
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ribosomal subunits to the cytoplasm. The role of ARF in limiting these steps of ribosomal
biogenesis results in the overall maintenance of protein synthesis in the cytoplasm.
Adapted from Saporita et al. 2007.
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Figure 1.4
Osteoclastogenesis. Osteoclasts are members of the monocyte/macrophage family.
Specific genes are sequentially activated as macrophages differentiate into mature,
resorbing osteoclast. Notably, RANKL, which is largely found on the membrane of
osteoblasts induces the commitment of cells to the osteoclast lineage. Adapted from
Teitelbaum and Ross, 2003.
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Figure 1.5
Arf loss affects osteoclastogenesis in vitro. (A) BrdU incorporation suggests there is no
difference between wild-type and Arf -/- macrophages. (B). BMMs differentiated for 3
days in the presence of M-CSF (1/20 vol) and 100ng/mL RANKL and then TRAP
stained. (C) Quantification of TRAP-positive cells with greater than five nuclei from day
3 osteoclast images (p = 0.01). (D) TRAP solution assay from equal numbers of day 4
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wild-type osteoclasts and day 4 Arf -/- osteoclasts. Cells were lysed and incubated in a
colorimetric assay with a substrate for TRAP (p =0.01) (E) Levels of serum TRAP from
age-matched wild-type and Arf -/- mice (p = 0.03, n=5). Adapted from Apicelli et al. 2008.
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Figure 1.6
Loss of NPM reverses the Arf -/- osteoclast phenotype. (A) NPM is knocked down by
lentivirus-targeted shRNA in wild-type and Arf -/- macrophages and confirmed by
immunoblotting. (B) Macrophages with or without NPM knockdown are differentiated is
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osteoclastogenic media for 6 days and then stained for TRAP. (C) TRAP activity is
quantified in day 6 osteoclasts. Loss of NPM reverses the Arf -/- osteoclast phenotype
such that they are equivalent to wild-type osteoclasts (p < 0.01). Adapted from Apicelli et
al. 2008.
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Chapter 2
Cathepsin K-Cre Causes Unexpected Germline
Deletion of Genes in Mice
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2.1 Abstract
Cathepsin K-driven Cre is reported to be active solely in osteoclasts and is the
most relevant tool for generating osteoclast-specific gene loss. We generated CtskCre/+;
ROSA+ mice and found Cre activity present in gametes, resulting in germline deletion of
genes upon breeding with floxed-gene mice. Together with our finding that CtskCre/+ mice
display enhanced estrogen levels, these results raise concerns regarding in vivo bone
phenotypes created using CtskCre/+ mice.
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2.2 Introduction and Results
Cathepsin K is a lysosomal cysteine protease of the papain family that is secreted
by osteoclasts during bone resorption and functions as the primary protease in the
degradation of type I collagen (Georges et al., 2009; Troen, 2004; Zaidi et al., 2001). In
partially replacing the Ctsk locus with Cre, one allele of Ctsk is lost; however, Ctsk+/mice are capable of maintaining normal bone turnover (Saftig et al., 1998). During mouse
development, Cathepsin K expression is highest in musculoskeletal tissues and
predominantly expressed in osteoclasts (Rantakokko et al., 1996). Furthermore,
expression of Cre mRNA in CtskCre/+ mice was demonstrated to be unique to bone, with
Cre activity evident only in osteoclasts (Nakamura et al., 2007).
In lieu of generating our own osteoclast-specific genetic mouse models, we first
sought to confirm that Cre activity was unique to osteoclasts in CtskCre/+ mice. Thus, we
crossed CtskCre/+ mice with Rosa+ reporter mice. Ovary and testis tissues from Rosa+;
CtskCre/+ mice were analyzed for Cre activity by LacZ staining. In ovaries of
CtskCre/+;Rosa+ mice, Cre activity was primarily detected in the oocytes and granulosa
cells, whereas Cre activity was not detected in Ctsk+/+;Rosa+ female mice (Figure 2.1a).
In testes, abundant staining was evident in spermatozoa, which are the haploid and
mature gametes. Again, Cre activity was not detected in Ctsk+/+;Rosa+ male mice (Figure
2.1b). This data demonstrates that Cathepsin K-driven Cre activity is present in gametes
of both female and male mice. Of note, only one Cre allele was necessary for DNA
excision at the Rosa locus. Given this data, we investigated the presence of Cre and
Cathepsin K mRNAs in ovary and testis tissues. We isolated ovary and testis RNA and
quantified Cathepsin K and Cre mRNA by qRT-PCR. In ovaries of 10-week-old wild-
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type mice, we detected Cathepsin K mRNA. Cathepsin K mRNA decreased as Ctsk was
replaced by Cre. Accordingly, we detected increasing amounts of Cre mRNA as
Cathepsin K mRNA decreased (Figure 2.2a,b). Similar results for Cathepsin K mRNA
were obtained using testes RNA from 8-week-old mice, albeit at much lower levels
relative to that observed in ovaries. Importantly, we again detected a dose-dependent
decrease in Cathepsin K mRNA as Cre mRNA levels increased in testes (Figure 2.2a,b).
Given the presence of Cathepsin K mRNA in ovaries, we analyzed ovary tissues from 16week-old mice for the presence of Cathepsin K by immunohistochemistry (IHC). Our
results indicate that Cathepsin K is expressed at the protein level in ovaries and is
primarily localized to oocytes within the developing follicles (Figure 2.2c). Furthermore,
we noted that follicles expressing Cathepsin K were primarily those in the early stages of
maturation. As a control, adjacent tissue sections were stained with or without primary
antibody. Sections incubated without antibody were negative for Cathepsin K in positive
areas of the adjacent section that was incubated with primary antibody (Figure 2.2c).
These results indicate that Cathepsin K is present in mouse ovaries and may be expressed
at a specific stage during follicle development.
To determine if CtskCre/+ mice would produce germline loss of a floxed gene, we
crossed CtskCre/+ mice with mice containing floxed exon1β of the ARF tumor suppressor
(Gromley et al., 2009). A primer set used to detect the presence of the 5’ loxP site in tail
DNA of Arf

fl/fl

mice was unable to amplify a product, suggesting the loss of template

(Figure 2.3). We next confirmed the presence of DNA using control primers. Again, the
results suggest that although DNA is clearly present in all samples, the primers we used
to detect the 5’ loxP site are unable to recognize a template. We therefore reasoned that
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exon1β of Arf was not present in the tail DNA. To test this, we used two different primers
sets that each contained a forward and reverse complementary sequence to a region of
DNA outside of the loxP sites (Figure 2.3). Both sets of primers resulted in products that
suggested the loss of exon1β (Figure 2.3). All results were repeated using DNA generated
from ear tissue (data not shown). To confirm germline Arf loss, we exploited the fact that
the testis is the only tissue in which others and we have been able to detect ARF protein
by IHC (Gromley et al., 2009). Testes from mice, in which exon1β of Arf had seemingly
been excised, were analyzed by IHC for ARF protein expression. While we detected ARF
in wild-type mice, we were unable to detect ARF protein expression in a mouse showing
loss of exon1β at the DNA level (Figure 2.4a). These results imply that one copy of Cre
under the control of the Ctsk promoter is sufficient to cause non-specific recombination
and result in germline Arf loss. Germline deletion of Arf in the mouse results in a 100%
penetrant spontaneous tumor formation phenotype. To confirm germline Arf loss, we
followed CtskCre/+; Arf

fl/fl

mice whose genotype indicated a loss of Arf to determine if

they would develop spontaneous tumors reminiscent of germline Arf-null animals. All
mice (100% penetrant) displayed a tumor type with the onset and tumor type comparable
to those published for traditional Arf-/- mice (Kamijo et al., 1999) (Figure 2.4b,c). This
data demonstrates that crossing mice containing a floxed gene with CtskCre/+ mice can
result in germline loss of the floxed gene. Finally, given that we observed Cathepsin K
expression in ovaries, we assessed whether loss of Ctsk in CtskCre/Cre mice would alter
serum estrogen levels. We examined the levels of estrogen (as measured by serum
estradiol) in wild-type and CtskCre/Cre (Ctsk-/-) mice. In the absence of Ctsk, estrogen
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levels doubled that observed in wild-type mice (Figure 2.5), implying that Cathepsin K
counteracts the production and/or release of estrogen into the blood of female mice.
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2.3 Discussion
Together, our results demonstrate that Cathepsin K is expressed in gametes and
this expression can result in germline excision of a floxed allele when using CtskCre/+
mice. Within the ovary, we observed Cathepsin K protein expression primarily in
oocytes. Data from Chiu et al. showing expression of Cathepsin K mRNA in mouse
ovaries supports this finding (Chiu et al., 2004). Expression of Cathepsin K has also been
noted in human ovary samples (Bromme and Okamoto, 1995). While there is no
published role for Cathepsin K in ovaries, our data showing that Cathepsin K may be
expressed during early stages of oocyte development suggests a possible role for
Cathepsin K during oocyte maturation. Moreover, other Cathepsins have also been shown
to be expressed during specific stages of follicle development in teleosts (Fabra and
Cerda, 2004). In testis, Cre activity was noted within seminiferous tubules and was
largely localized to mature spermatozoa. To support this finding, when creating
transgenic mice that express Cre driven by the Ctsk promoter, Chiu et al. published the
expression of Cre expression in the testis of multiple mouse lines (Chiu et al., 2004).
Upon crossing CtskCre/+ mice with Arf fl/fl mice, we generated germline Arf loss as
demonstrated by PCR, IHC for ARF in testis, and disease phenotypes that mimic
traditional Arf-null mice (Kamijo et al., 1999). These findings place into question
previous data that has been generated using mice containing Cre driven by the Ctsk
promoter to create osteoclast-specific knockouts (Chiu et al., 2004; Nakamura et al.,
2007). We are not suggesting that all animal models with Cre under the control the Ctsk
promoter will result in a genomic knockout as neither every follicle nor seminiferous
tubules was positive for Cre activity. However, our data clearly indicate that careful
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testing is necessary when using this mouse model to ensure that the intended gene
excision has occurred only in osteoclasts and that results are correctly interpreted. It is
especially important to consider a genotyping result in which both alleles appear to be
floxed (based on a tail DNA sample); it is possible that this result reflects one floxed
allele and one null allele (Figure 2.6). Finally, our results indicate that loss of Cathepsin
K results in significantly increased circulating levels of estradiol, a well-studied regulator
of bone physiology (Manolagas et al., 2002). Given that estrogen suppresses osteoclast
activity while enhancing osteoblast activity, enhanced estrogen upon loss of Cathepsin K
in ovaries may inadvertently affect the bone phenotype of an intended conditional
knockout mouse.
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2.4 Methods
Generation of CtskCre/+;Rosa+ and CtskCre/+;Arf fl/fl mice.
All animals were used in protocols that were reviewed and approved by the
Washington University Animal Studies Committee.

CtskCre/+ mice and the Rosa+

reporter mice have been described previously (Nakamura et al., 2007; Soriano, 1999).
Cathepsin K-Cre “knockin” heterozygous mice (CtskCre/+; maintained on a C57BL/6
background) were crossed with mice heterozygous for an R26R allele, where a
constitutively active chromosomal gene was manipulated to insert the lacZ gene such that
the β-galactosidase protein is produced only following the removal of a “stuffer”
fragment flanked by loxP sites (Rosa+; maintained on a C57BL/6 background) to
generate CtskCre/+; Rosa+ mice. Ctsk+/+; Rosa+ mice served as controls. CtskCre/+ mice
were also crossed with mice homozygous for a floxed allele of Arf where exon1β is
flanked by loxP sites (Arf

fl/fl

; maintained on a mixed background of C57BL/6 and

129SvJae, a kind gift from C. Sherr, St. Jude Children’s Research Hospital) to generate
CtskCre/+; Arf

fl/+

. Subsequent rounds of matings of these offspring eventually yielded

CtskCre/+; Arf

fl/fl

mice. Cohorts of these mice as well as other siblings consisting of

various combinations of Cre and floxed Arf alleles were viable and fertile and also used
for breeding in our studies. Tail and/or ear snips were used to prepare DNA for PCRbased genotyping as previously described (Truett et al., 2000). Ctsk wild-type and Creknockin

alleles

were

detected

using

primers

Ctsk-P1

5’-

TTATTCCTTCCGCCAGGATG-3’, Ctsk-P2 5’-TTGCTGTTATACTGCTTCTG-3’ and
Ctsk-P3 5’-TAGTTTTTACTGCCAGACCG-3’. When used together in a PCR reaction,
a wild-type allele generates a 135bp fragment whereas the presence of Cre produces a
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300bp fragment. Arf wild-type and floxed alleles were determined by using primers
SpeLxF-30 5’-TTGCTACTTTACTGCAGCCAGACCACTAGG-3’ and SpeLxR-30 5’CTCGGAGATTGAGAAAGCGGGAAGTCAAGC-3’ in which the wild-type allele
generates a 260bp product and the floxed allele generates a 360bp product. The presence
of the R26R allele was assessed by amplification of a 320bp fragment using primers
R26Rfwd

5’-AAAGTCGCTCTGAGTTGTTAT-3’

and

R26Rrev

5’-

GCGAAGAGTTTGTCCTCAACC-3’. See Figure 2.3a for a list of primers and product
sizes used to determine Arf recombination.

Tissue harvest and histology.
Testis and ovary tissues were taken from mice that were cardiac perfused with
formalin, then fixed using a rapid microwave fixation technique (Lu et al., 2007). Fixed
tissues were PBS washed then processed through graded alcohols and xylenes then
embedded in paraffin. 5-μm tissue sections were immunostained. Alternatively, frozen
testis and ovary tissues were prepared from sucrose-perfused mice, embedded in OCT
over liquid nitrogen, sectioned at 5-μm and LacZ stained.

Immunostaining.
All sections were deparaffinized, rehydrated, washed in PBS, and blocked with
serum-free Protein block (Dako) for 30min at room temperature. All immunostaining
required antigen retrieval which was performed in a food steamer using a 1X Reveal
decloaker buffer (pH 6.0, Biocare Medical). Antibodies for the following markers were
diluted in Antibody diluents (Dako) and applied overnight at 4°C: rat anto-p19ARF (1:400,
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Abcam) and rabbit anti-Cathepsin K (1:200, Abcam). A secondary antibody conjugated
to Alexa Fluor 488 was incubated on tissue sections for 1hr at room temperature (1:300,
Invitrogen). Nuclei were counterstained using SlowFade Gold Antifade reagent with 4’,6diamidino-2-phenylindole (DAPI) (Invitrogen).

Quantitative real-time PCR.
Ovary and testis tissues were isolated, flash-frozen in liquid nitrogen, and
homogenized in RNA-Solv (Omega Bio-Tek). The SuperScript III first-strand synthesis
system (Invitrogen) was used to generate first strand cDNA.

Real-time PCR was

performed with iQ SYBR Green Supermix (Bio-Rad) on an iCycler thermal cycler (BioRad).

LacZ staining.
Frozen sections were air-dried for 30min at room temperature, then fixed in 2%
paraformaldehyde/0.125% glutaraldehyde in 1x PBS pH 7.4 for 5min. Sections were
then washed sequentially in 2mM MgCl2 /PBS and 2mM MgCl2, 0.02% Nonidet P40,
0.01% deoxycholate in PBS. Tissue sections were then washed briefly in LacZ staining
buffer (5mM potassium ferrocyanide, 5mM potassium ferricyanide, 2mM MgCl2, 1xPBS)
and incubated in LacZ staining buffer supplemented with 1mg/ml X-Gal overnight at
37oC with gentle shaking. Tissue sections were washed in diH2O briefly and nuclei were
counterstained with Nuclear Fast Red (Dako).

Microscopy and imaging.
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Gross pathological images were captured using a Sony Cyber-shot 12.1 megapixel
digital camera equipped with a Carl Zeiss 5x optical zoom wide (28mm) lens.
Microscopy images for histology were obtained with a BX61 microscope (Olympus
America), using the following objectives: UPlan Apochromatic 20X/NA 0.70 and UPlan
Apochromatic 40X/NA 0.85. Tissue sections stained with LacZ were mounted with
Krystalon (EMD) and coverslipped. Histological microscopy images were obtained with
a DP70 color Bayer mosaic digital camera, Peltier device cooled to -10oC (Olympus
America). These images were captured with MicroSuite Biological Suite version 5
software (Olympus Soft Imaging Solutions) and resized and formatted with Adobe
Photoshop CS3 software (Adobe Systems Incorporated).

Fluorescence microscopy

images were obtained with an Eclipse 90i microscope (Nikon) using the following
objectives: Plan Apochromatic 10x/NA 0.45, Plan Apochromatic 20x/NA 0.75, and Plan
Apochromatic Oil 100x/NA 1.40. Tissue sections for fluorescence microscopy images
were mounted with SlowFade Gold Antifade reagent with DAPI (Invitrogen),
coverslipped, and images were obtained using a CoolSnap HQ2 monochrome digital
camera, Peltier cooled to -30oC (Photometrics). Fluorescence images were captured with
MetaMorph version 7.6 software, (MDS Analytical Technologies) and resized and
formatted with Adobe Photoshop CS3 software (Adobe Systems Incorporated).

Estradiol Analysis.
Serum estradiol was measured using the Estradiol EIA Kit (Cayman Chemical).
The developed color intensity is inversely proportional to the amount of free hormone in
each sample and was quantified using an iMARK microplate reader (Bio-Rad).
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Statistical analysis.
Data were analyzed using Excel (Microsoft Office). Results are expressed as the
mean ±SD, and statistical significance was determined using a two-tailed t-test.
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Figure 2.1.
Cre activity is present in the gametes of CtskCre/+ mice. Reproductive organs of
indicated genotypes were analyzed for Cre activity by LacZ staining. (A) In ovaries of
Rosa+; CtskCre/+ mice, Cre activity was detected in oocytes and cells surrounding the
developing oocytes (left panel). Controls were negative for LacZ staining (right panel).
Scale bar = 50μM. (B) In testes of Rosa+; CtskCre/+ mice, Cre activity was detected
primarily in spermatozoa (left panel). Controls were negative for LacZ staining (right
panel). Scale bar = 100μM.
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Figure 2.2.
Cathepsin K and Cre are detected in ovary and testis tissues. (A) Quantitative RTPCR was used to quantify the presence of Cathepsin K mRNA (blue) and Cre mRNA
(red) in ovary (left) and testis (right) for all indicated genotypes (n=3). Histone 3.3 was
used as a control. Data are represented as means ±SD. A two-tailed t-test was used to
generate indicated p values. (B) DNA was extracted from the tails of mice used for
quantitative RT-PCR analysis to verify their genotypes. The top bands indicate the
presence of Cre. The bottom band is indicative of a wild-type Cathepsin K allele. (C)
Ovaries from WT mice analyzed by IHC for Cathepsin K. Top panels, scale bar =
200μM. Bottom, left panel shows staining without primary antibody. An adjacent section

81

to the control (bottom, middle) was incubated with primary antibody (scale bar =
100μM). Red box indicates positively-stained oocyte (bottom, right scale bar = 20μM).
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362 bp
1851 bp
1998 bp

KO
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Figure 2.3.
Crossing Arf fl/fl mice with CtskCre/+ mice results in germline Arf loss. (A) Three sets of
primer pairs were designed to detect the presence of floxed exon 1beta, which is unique
to Arf. Controls are mice that were never crossed with CtskCre/+ mice. (B) PCR products
were not detected upon genotyping new mice for the presence of the 5’ loxP site using
the first set of primers: LoxF/LoxR-1 (far left panel). This cannot be attributed to an
absence of DNA as control primers detect DNA in all lanes (left middle panel). Two sets
of primer pairs were used to detect the presence of exon 1beta. LoxF/ArfR results in a
product size of 298bp in new mice, indicating a loss of exon1β (left middle panel).
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LoxF/LoxR-2 results in a product size of 445bp when genotyping new mice, indicating a
loss of exon1β (far right panel). (C) Primer sets used to detect the presence of exon 1beta
in wild-type mice give a product of 1798bp (LoxF/LoxR-2, left) or 1651bp (LoxF/ArfR,
right).
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Figure 2.4.

Crossing Arf

fl/fl

mice with CtskCre/+ results in germline Arf loss. (A)

Immunofluorescent staining for ARF in testis tissues indicates the loss of exon 1β at the
protein level (scale bar = 100μM). (B,C) CtskCre/+; Arf fl/fl mice phenocopy traditional Arf /-

mice, displaying both (B) lymphomas and (C) fibrosarcomas.
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Figure 2.5.
Homozygous loss of Cathepsin K enhances serum estradiol levels. Serum from Ctsk+/+
(wild-type, n=3) and CtskCre/Cre (Ctsk -/-, n=3) mice was analyzed for estradiol. Data are
represented as means ±SD and p value was generated using a two-tailed t-test.
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Figure 2.6.
Genotyping results can be misinterpreted when breeding floxed mice with CtskCre/+
mice. (A) DNA was extracted from tails of mice and genotyped for the presence of the
exon 1β loxP site. The presence of a loxP site results in a 362bp band. In the absence of
loxP (i.e. WT Arf), the band is 262bp (refer to Figure 2.3a for map). Controls are mice
that were not bred with CtskCre/+ mice. Mice of interest are highlighted in yellow. Note
that left mouse of interest appears to be Arf +/+ and right mouse of interest appears to be
Arf

fl/fl

. (B) DNA from mice of interest are genotyped to detect the presence of exon 1β

using LoxF/ArfR primers, which generate a band of 298bp if exon 1β is absent (refer to
Figure 2.3a for map). Genotyping results indicate that exon 1β is absent on at least one
allele. Thus, the mice of interest are actually Arf +/-(left) and Arf
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fl/-

(right).
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Chapter 3

The Role of ARF in Osteoclasts
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3.1 Abstract
The ARF tumor suppressor is upregulated upon oncogenic stress and can halt
proliferation in both p53-dependent and -independent mechanisms. With a focus on p53independent ARF tumor suppression, we have previously demonstrated that basal ARF
can suppress ribosome biogenesis, in part through the negative regulation of
nucleophosmin, to ultimately suppress protein synthesis . Importantly, these findings
were demonstrated using dividing mouse embryonic fibroblasts. Given that protein
synthesis and the cell cycle are coordinately controlled, we questioned whether basal
ARF regulates protein synthesis in a proliferation-independent context. Here we use the
osteoclast as a model to study post-mitotic growth in a physiologically-relevant setting
where protein synthesis is necessary for proper function.
Our results show that Arf loss enhances osteoclastogenesis in vitro as
demonstrated by increased OC number and size, protein markers of osteoclastogenesis,
and increased bone resorption relative to wild-type osteoclasts. Notably, enhanced
osteoclastogenesis upon Arf loss is independent of both proliferation and p53.
Furthermore, we demonstrated that ARF and NPM colocalize in wild-type osteoclasts,
suggesting that ARF may be stiffening protein synthesis to maintain either
osteoclastogenesis, osteoclast function, or both. Subsequent data revealed enhanced
protein synthesis and ribosome activity during osteoclastogenesis upon Arf/ loss relative
to wild-type. To determine if ARF regulation of osteoclastogenesis has an impact on bone
resorption in vivo, we generated radiation chimeras and challenged them with RANKL.
We found that Arf loss results in elevated bone resorption as determined by a decrease in
trabecular bone volume and bone mineral density. We confirmed that the increase in bone
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resorption is due, at least in part, to increased osteoclastogenesis in vivo. This data
collectively suggests that ARF regulates proliferation-independent cell growth, and is a
function that is physiologically-relevant both in vitro and in vivo.
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3.2 Introduction
The locus encoding the ARF tumor suppressor is unique in that it also encodes the
p16INK4a tumor suppressor protein. In fact, these two tumor suppressor share two of their
three exons and thus significant homology at the DNA and mRNA level. However, the
first exon of Arf (exon1β) is distinctive and splices into the shared exons 2 and 3 such
that Arf is translated in an alternative reading frame (hence the ARF moniker) (Quelle et
al., 1995; Sherr, 2000). Given the arrangement of these two potent tumor suppressors, it
is important that the cell tightly regulate this locus. Under normal conditions, the locus is
repressed by polycomb repressive complexes (Aguilo et al.). However, in a state of
oncogenic stress, the locus is turned on to regulated cell growth and proliferation.
ARF and INK4a are also distinctive in their mechanisms of tumor suppression.
INK4a inhibits the cyclin D-dependent kinases, Cdk4 and Cdk6, from phosphorylating
the retinoblastoma (Rb) tumor suppressor. In a hypophosphorylated state, Rb remains
bound to E2F transcription factors, which prohibit them from transcriptionally instructing
the cell to enter S phase (Serrano et al., 1993; Sharpless, 2005; Sherr, 1996). The ARF
tumor suppressor is classically known to bind and sequester MDM2 in the nucleolus
(Weber et al., 1999). This prevents MDM2 from interacting with p53, which is known to
result in the shuttling of p53 into the cytoplasm, and act as an E3 ligase in the
ubiquitination and targeting of p53 for proteasomal degradation (Haupt et al., 1997;
Honda et al., 1997; Kubbutat et al., 1997; Roth et al., 1998). Interestingly, it was
subsequently demonstrated that ARF overexpression can arrest p53/Mdm2-null and
Arf/p53/Mdm2-null (designated triple knock-out or TKO) mouse embryonic fibroblasts
(MEFs) (Weber et al., 2000a). Moreover, TKO mice develop a wider spectrum of tumors
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and at a greater frequency compared to mice lacking both p53 and Mdm2 or p53 alone
(Weber et al., 2000a). These data were the first to genetically demonstrate that ARF can
act as a tumor suppressor independently of its ability to regulate p53 activity. Since this
study, a flurry of work has amounted to a list of around 30 ARF-interacting proteins that
are believed to be important for ARF’s p53-independent tumor-suppressive functions
(Sherr, 2006). Among this list is nucleophosmin (NPM), which is known to be important
for growth and development in mice (Grisendi et al., 2005) and has been attributed a
variety of roles in cancer progression (Bernard et al., 2003; Brady et al., 2009; Grisendi et
al., 2006; Nozawa et al., 1996; Shields et al., 1997; Skaar et al., 1998; Subong et al.,
1999; Tanaka et al., 1992). NPM is one of the most characterized ARF-interacting
proteins. It is well-known for its ability to shuttle between the nucleus and cytoplasm
(Kang et al., 1974; Kang et al., 1975). In doing so, NPM transports key components of
the ribosomal machinery to the cytoplasm for translation (Maggi et al., 2008; Yu et al.,
2006). In fact, NPM is known to be a rate-limiting factor for protein translation as its loss
results in decreased protein output and a build-up of ribosomes at the interior perimeter of
the nucleus (Maggi et al., 2008). Importantly, ARF has been shown to counteract the
nucleocytoplasmic shutting of NPM and, in this manner, acts as a p53-independent tumor
suppressor (Brady et al., 2004).
The importance of ARF as a tumor suppressor is evident given that mice in which
exon 1β has been specifically deleted begin developing tumors as early as 8 weeks of age
(Kamijo et al., 1999). After one year, 80% of the mice succumb to spontaneous tumor
development, namely sarcomas and lymphoid malignancies. Arf +/- mice also develop
tumors, albeit after a longer latency relative to Arf -/- mice (Kamijo et al., 1999). In
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humans, the locus encoding Arf is the second most commonly mutated locus (Hainaut et
al., 1997; Hall and Peters, 1996). While it is often difficult to determine the individual
roles of the multiple tumor suppressor encoded by the locus in human cancer, there are
specific cases in which only Arf is affected. For example, deletion or mutation of Arf has
been reported in glioblastoma patients, melanoma patients, and a family with melanomaneural system tumor syndrome (Laud et al., 2006; Nakamura et al., 2001; RandersonMoor et al., 2001; Rizos et al., 2001). Furthermore, the Arf promoter is known to be
methylated and consequently silenced in many human cancers (Furonaka et al., 2004;
Kominami et al., 2009; Konishi et al., 2002; Melendez et al., 2000; Zemliakova et al.,
2004; Zheng et al., 2000).
As previously mentioned, normal conditions require that ARF levels be kept low,
and thus ARF is nearly undetectable in the absence of oncogenic stress. Still, various
functions have recently been ascribed to these basal levels of ARF. One of the first
described roles of basal ARF was initiated based on the observation that Arf -/- mice have
eyes that are slightly smaller than their wild-type counterparts (Kamijo et al., 1999;
Kamijo et al., 1997; McKeller et al., 2002). Studies have since demonstrated that the
hyaloid vascular system (HVS) in the vitreous of the eye fails to regress in the absence of
Arf (McKeller et al., 2002). Using Arf Gfp/+ mice to more closely examine the localization
of ARF within the developing eye, it was determined that ARF was expressed in mural
cells expressing platelet-derived growth factor receptor β (Pdgfrβ) (Silva et al., 2005). In
the absence of Arf, these cells abnormally proliferate, which causes the persistent HVS
and ultimately leads to blindness in Arf -/- mice (Gromley et al., 2009; Silva et al., 2005).
Notably, p53-/- mice have normal vision (McKeller et al., 2002), and thus the role of basal
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ARF in eye development is independent of its ability to regulate p53 activity. The use of
Arf Gfp/+ mice also revealed the expression of ARF in male spermatogonia, which are the
cells that line the basement membrane of each seminiferous tubule and differentiate into
mature spermatozoa as they progress through meiosis I and meiosis II moving toward the
lumen of the tubule (Cole et al.; Gromley et al., 2009). In the absence of Arf,
spermatogonia have heightened levels of apoptosis, which limited data suggests is the
result of an increase in phosphorylated histone H2AX (Churchman et al.). Ultimately, the
enhanced apoptosis during germ cell development upon Arf loss results in reduced sperm
number compared to that in wild-type mice (Churchman et al.; Cole et al.). While the
apoptosis of these cells in p53-dependent, ARF's regulation of H2AX phosphorylation is
independent of p53 (Churchman et al.).
Basal ARF has also been shown to regulate osteoblastogenesis and osteoblast
activity. Osteoblasts are the bone-forming cells of the skeleton. Thus, the role of ARF in
osteoblasts is especially important given that our work here has focused on the role of
ARF in osteoclastogenesis and the regulation of bone resorption in vivo. In the presence
of osteogenic media in vitro, Arf -/- stromal cells exhibit enhanced osteoblastogenesis
compared to wild-type stromal cells (Rauch et al.). This finding can, at least partially, be
attributed to an increase in the proliferation of osteoblast precursor cells (unpublished
communicated data). ARF's ability to regulate osteoblastogenesis is also relevant in vivo
as long bones from Arf -/- mice have heightened levels of osteoblast differentiation
markers, which correlates to increased bone formation (Rauch et al.). Furthermore, Arf -/mice display an overall increase in trabecular bone volume and bone mineral density
when assessed by microCT (Rauch et al.).
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Given the nucleolar localization of ARF and its previously reported roles in
regulating the nucleocytoplasmic shuttling of NPM, our lab has recently examined the
role of basal ARF in regulating nucleolar structure and function to limit protein synthesis
in mouse embryonic fibroblasts (MEFs). We have shown that Arf loss results in an
increase in both the size and number of AgNORs, which is indicative of abnormal
nucleolar function (Apicelli et al., 2008). Given that nucleoli house the proteins required
for the initial steps in ribosome biogenesis, Apicelli and colleagues examined protein
synthesis upon basal Arf loss beginning with the transcription of ribosomal DNA
(rDNA). Data suggest that Arf loss not only enhances the transcription of rDNA but also
the processing of the newly transcribed 47S transcript into intermediate precursors that
lead to the final 5.8S, 18S, and 28S subunits, both of which are functions that have
previously been ascribed to ARF (Apicelli et al., 2008; Ayrault et al., 2006; Ayrault et al.,
2004; Qi et al., 2004; Sugimoto et al., 2003). Furthermore, in accordance with ARF's
ability to bind and restrain NPM, loss of basal Arf exacerbated the export of ribosomes
from the nucleus to the cytoplasm (Apicelli et al., 2008). Ultimately, the increases in
ribosomal biogenesis upon Arf loss resulted in enhanced protein synthesis relative to that
observed in wild-type MEFs (Apicelli et al., 2008). In an effort to translate these findings
into a physiologically-relevant cell model with a requirement for protein synthesis,
Apicelli and colleagues initiated the study of basal ARF function in osteoclasts. The data
show that Arf loss appears to enhance overall osteoclastogenesis after 3 days of treatment
with M-CSF and RANKL . In the absence of Arf, there were a greater number of TRAPpositive osteoclasts with more than five nuclei (Apicelli et al., 2008). Arf loss also
appears to enhance the function of osteoclasts in vitro as wild-type bone marrow
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macrophages (BMMs) allowed to differentiated one day longer than Arf -/- BMMs in
osteoclastogenic media still did not exhibit as much TRAP activity as the Arf -/osteoclasts (Apicelli et al., 2008). These differences translate into what is observed in
vivo, where serum TRAP levels are elevated in the absence of Arf. This change could not
be attributed to an increase in the number of macrophages upon Arf loss as assessed by
BrdU incorporation in vitro (Apicelli et al., 2008). Here, we expanded upon these initial
findings to definitively determine if basal ARF regulates osteoclasts and whether this
regulation is relevant in vivo. Additionally, we aimed to determine the mechanism
through which ARF acts in this post-mitotic setting.
After 5 days of culturing bone marrow macrophages (BMMs) in the presence of
M-CSF and RANKL, we quantified an increase in both the size and number of mature
osteoclasts in absence of Arf. Enhanced osteoclastogenesis was also confirmed by TRAP
and Cathepsin K protein levels and pit staining. Importantly, we could not attribute the
difference between wild-type and Arf-null osteoclasts to enhanced proliferation either
before (as previously shown) or after the addition of RANKL. Furthermore, this is a p53independent function of ARF as BMMs isolated from p53-null mice did not phenocopy
those from Arf-null mice when differentiated in vitro. Instead, p53-/- osteoclasts closely
resembled wild-type osteoclasts, which is in accordance with previously published
findings (Wang et al., 2006). Given the known roles of ARF in regulating protein
synthesis, we questioned whether ARF might be regulating osteoclastogenesis by limiting
protein synthesis during differentiation. Our data demonstrate that Arf loss results in
enhanced protein production, especially in pre-OCs (day 3 of differentiation) and mature
OCs (day 5 of differentiation). In part, this appears to be due to increased ribosome
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output upon Arf loss in pre-OCs. Finally, we wanted to know if our in vitro results would
translate to increased bone resorption upon Arf loss in vivo. We generated radiation
chimeras, in which wild-type mice either received wild-type or Arf -/- bone marrow. Our
results demonstrate that Arf loss causes a significant increase in bone resorption and bone
mineral density compared to mice with wild-type osteoclasts. Taken together, these
results point towards a physiologically-relevant role of basal ARF in regulating
proliferation- and p53-independent cell growth.
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3.3 Methods
Mice
Arf -/- mice were maintained on a 129X1/SvJ x C57BL/6 background. Agematched wild-type controls on the same background were used except where noted. All
mice were housed in a pathogen-free animal facility, fed standard chow ad libitum, and
treated following animal protocols approved by the Washington University Animal
Studies Committee.

Osteoclast culture
Whole bone marrow was isolated from the femurs and tibias of wild-type, Arf -/-,
and p53-/- mice. Macrophages were grown in α-minimal essential medium (α-MEM)
containing 10% fetal bovine serum (FBS) and CMG14-12 culture supernatant (1/10 vol)
as a source of M-CSF. Osteoclasts were generated from bone marrow macrophages using
CMG14-12 supernatant (1/100 vol or 1/50 vol) and recombinant GST-RANKL
(50ng/mL). To assess for RANKL hypersensitivity, all wells were identically treated
except for the indicated amounts of RANKL (12.5, 25, 50, or 100 ng/mL). In 48-well
tissue culture dishes, BMMs were plated at 1.5 X 104 cells per well. Osteoclasts were
fixed and visualized by histochemical staining for tartrate-resistance acid phosphatase
according to the manufacturer’s protocol (Sigma).

quantitative RT-PCR, and Immunoblotting
RNA and protein were isolated from all cells using the illustraTM triplePrep kit
(GE Healthcare) as described in the manufacturer’s protocol. For qRT-PCR, first-strand
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cDNA was prepared using the SuperScript III first-strand synthesis system (Invitrogen).
Real-time PCR was performed with iQ SYBR Green Supermix (Bio-Rad) according to
the manufacturer's protocol. Primer sequences TRAP forward: 5’CAGCTCCCTAGAAGATGGATTCAT-3’ and reverse: 5’GTCAGGAGTGGGAGCCATATG-3’ and Cathepsin K forward: 5’ATGTGGGTGTTCAAGTTTCTGC-3’ and reverse: 5’CCACAAGATTCTGGGGACTC-3’ Protein was eluted in 7M Urea and further diluted
to 3M Urea such that protein concentration could be quantified by Bradford assays.
Antibodies used included rabbit anti-Cathepsin K (Abcam) and goat anti-TRAP (Santa
Cruz).

Proliferation analysis
Macrophages were cultured in the absence of RANKL or in the presence of
50ng/mL RANKL for 24h on glass coverslips in 24-well plates. Cells were labeled with
bromodeoxyuridine (BrdU) for 24h, fixed, and then stained with DAPI and an antibody
against BrdU. BrdU-positive cells were blindly counted for each experiment.

Apoptosis analysis
Macrophages were seeded at 5000 cells/well in 96-well dishes and differentiated
in the presence of M-CSF and 50ng/mL RANKL. Cell death was assessed by cell death
detectio ELISAPLUS kit (Roche Applied Sciences), which detects cytoplasmic histoneassociated DNA fragmentation. Absorbance was measured at 405nm.
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In vitro bone resorption
Bone marrow macrophages from either wild-type or Arf -/- mice were
differentiated in vitro on bovine bone slices in the presence of M-CSF and 50ng/mL
RANKL. After 8 days in the presence of osteoclastogenic media, cells were removed
from bone by mechanical agitation. Bone slices were then incubated with peroxidaseconjugated wheat germ agglutinin (Sigma) followed by 3,3-diaminobenzidine (Sigma) to
visualize areas of bone Resorptive area was blindly quantified by determining the average
of four fields from each bone slice.

Immunofluorescence
Wild-type bone marrow macrophages were cultured in the presence of M-CSF
and 50ng/mL RANKL for 6 days on glass coverslips in 24-well plates. Cells were then
fixed with ice-cold methanol:acetone (1:1 vol) and stained with rat anti-ARF and rabbit
anti-NPM followed by FITC-conjugated anti-rabbit and rhodamine-conjugated anti-rat.
Nuclei were visualized with DAPI.
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S-methionine incorporation assays
Bone marrow macrophages were plated in 6-well dishes in the presence of only

M-CSF (BMMs) or M-CSF and 50ng/mL RANKL (pre-OCs and OCs). All cells were
starved of methionine and cysteine for 30min prior to labeling at the appropriate time
point during differentiation (3 days post-RANKL for pre-OC and 5 days post-RANKL
for OCs). Following starvation, cells were pulsed with 150 μCi of
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S-mehtionine for the

indicated times (2, 4, or 8 hours). The first time point (t=0) was harvested immediately
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after the pulse. Following the pulse, cells were washed with cold phosphate-buffered
saline and then lysed with 1% Triton X-100 buffer. Protein was precipitated from cell
lysates using 10% tricholoroacetic acid and pellets were analyzed by liquid scintillation
counting to quantify the incorporated counts per million.

Ribosome fractionation
3 x 106 cells per condition were treated with 50ug/mL cycloheximide for 10min.
Cells were then mechanically lifted and lysed. Cytoplasmic fractions were separated by
centrifugation and layered over a continuous sucrose gradient. Gradients were
fractionated and RNA absorbance was monitored at 254nm.

Histology
Bones were isolated within 24h following the final dose of RANKL and fixed in
formalin overnight. Fixed bones were then decalcified for 14 days in 14% EDTA and
subsequently dehydrated in increasing amounts of EtOH. Paraffin-embedded sections
were stained for tartrate-resistant acid phosphatase and quantified using Bioquant Osteo
(Bioquant Image Analysis).

AgNOR staining
Bone marrow macrophages were seeded on glass coverslips and assessed for
AgNORs at the indicated times according to a modified protocol that was originally
presented by Aubele et al. (Aubele et al., 1994). Briefly, cells were first fixed in 2%
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glutaraldehyde and then 3:1 ethanol-acetic acid solution. Cells were subsequently stained
using a 0.33% formic acid-33.3% silver nitrate solution in 0.66% gelatin and then
mounted on slides using Vectashield. AgNOR numbers were blindly quantified.

Generation of radiation chimeras
7 week-old wild-type mice on a 129X1/SvJ x C57BL/6 background were lethally
irradiate (1000 rads). After 24 hours, 1 x 106 donor whole bone marrow cells (either from
wild-type or Arf -/- mice) were intravenously transferred into the tails of recipient mice.
Hematopoietic reconstitution with the donor genotype was confirmed by PCR of
peripheral blood.

viva CT analysis
Tibias were scanned from the proximal epiphysis to the tibia-fibula junction by in
vivo microCT (VivaCT 40, Scanco Medical, calibrated at regular intervals by single
individual).We assessed bone parameters by blindly contouring 30 sections below the
growth plate of each tibia to exclude cortical bone. For all measurements, a threshold of
180 (on a 0-1000 scale) was maintained.
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3.4 Results

Arf loss accelerates osteoclastogenesis in vitro
To definitively determine whether Arf loss was affecting osteoclastogenesis in
vitro, we first isolated bone marrow macrophages (BMMs) from WT and Arf -/- mice.
After five days in the presence of M-CSF (1/100 vol) and 50ng/mL RANKL, we
confirmed that the osteoclasts were either WT or Arf-null by PCR (Figure 3.1a) and
Western analysis (Figure 3.1b). The cells were TRAP-stained for quantification (Figure
3.2a), and we observed an increase in the number of TRAP-positive multinucleated
osteoclasts (Figure 3.2b), indicating that Arf loss enhances osteoclastogenesis in vitro.
The total area quantified was also greater in the absence of Arf (Figure 3.2c), indicating
that Arf -/- osteoclasts are larger than their wild-type counterparts (Figure 3.2d).
Furthermore, when differentiating BMMs under various concentrations of RANKL, we
found that loss of Arf permitted osteoclastogenesis even in the presence of very low
RANKL concentrations (Figure 3.3a). Furthermore, in these osteoclast differentiation
experiments, Arf loss resulted in an increase in the number, area covered by osteoclasts,
and osteoclast size at all concentrations of RANKL relative to wild-type cells (Figure
3.3b-d). During differentiation, we noted that osteoclasts were forming much earlier in
the absence of Arf (observation not quantified). To affirm this observation, we isolated
cells on each day during osteoclastogenesis for five days and assessed both the mRNA
and proteins levels of two well-characterized markers of osteoclastogenesis: tartrateresistant acid phosphatase (TRAP) and Cathepsin K (Zhao et al., 2007). Interestingly, the
mRNA levels did not appear any earlier in the absence of Arf, but they were significantly
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increased in the absence of Arf relative to wild-type (Figure 3.4), which suggests that Arf
loss may also enhance osteoclast function in addition to exacerbating osteoclastogenesis.
The protein levels of both Cathepsin K and TRAP support accelerated osteoclastogenesis
in the absence of Arf. Cathepsin K protein levels were 19-fold greater by 4 days postRANKL and 31-fold greater by day 5 compared to the levels on day 3 in WT cells. In
comparison, Arf -/- cells had an 8-fold increase in Cathepsin K on day 3 compared to WT
day 3 and by 4 days post-RANKL, the Arf -/- cells already exhibited levels of Cathepsin K
(30-fold) that were comparable to that of day 5 WT cells (Figure 3.5). Similarly, TRAP
levels observed after 5 days post-RANKL in WT cells were comparable to those seen
only 4 days post-RANKL treatment in Arf -/- cells (Figure 3.5). Taken together, this data
suggests that loss of Arf enhances osteoclastogenesis in vitro, resulting in both increased
number and size of osteoclasts. It is possible that Arf loss results in increased osteoclast
size as a result of enhanced fusion of mononuclear precursors. To evaluate this, we
counted the number of nuclei per cell in WT and Arf -/- osteoclasts. Blinded quantification
results suggest that there is no difference in the numbers of nuclei between WT and Arf -/osteoclasts, implying that enhanced fusion does not explain the increase in size upon Arf
loss (Figure 3.6). As I will discuss later in this section, the increased size may be a result
of enhanced protein synthesis during osteoclastogenesis as a result of Arf loss. Finally, to
determine whether the increased osteoclastogenesis in Arf -/-cells results in more bone
resorption in vitro, WT and Arf -/- macrophages were differentiated on bovine bone slices
in the presence of M-CSF and RANKL for 8 days. The bone slices were then analyzed
for resorption by staining and quantifying pit area (Figure 3.7a). After 8 days, less than
5% of the bone slices were covered in pits when plated with WT BMMs. However, we
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found that Arf loss results in approximately 25% of the bone slice being covered with pits
(Figure 3.7b). This data compliments our previous results suggesting that Arf loss results
in enhanced osteoclastogenesis. More importantly, it suggests that while Arf loss
accelerates osteoclastogenesis, differentiation still proceeds properly and results in active
and functional osteoclasts in vitro.

Enhanced osteoclastogenesis: analyzing proliferation, apoptosis, and p53
To determine if Arf loss results in increased osteoclast number and size as a result
of enhanced precursor proliferation, we quantified BrdU-positive nuclei before and after
the addition of RANKL. In accordance with previously published data analyzing the
proliferation of BMMs upon Arf loss (Apicelli et al., 2008), we did not observe an
increase in proliferation in Arf -/- cells relative to WT (Figure 3.8a). As a control, we also
assessed proliferation on days 3 and 4 of osteoclastogenesis. As expected, our results
show that there is very little proliferation occurring by day 3 of osteoclastogenesis
(Figure 3.8b). An increase in either osteoclast number or size could also be a result of
decreased apoptosis. To assess whether Arf loss alters apoptosis in vitro, we examined
cells 4, 5, 6, and 7 days after RANKL treatment as this is the timeframe in which we
typically observe cell death. Apoptosis was quantified by an ELISA assessing histoneassociated DNA fragmentation. On days 4, 5, and 6, we observed slight decreases in
apoptosis in Arf -/- cells relative to WT. The most striking difference was observed on day
7; Arf loss significantly decreases the levels of fragmented DNA nearly 2-fold compared
to that observed in WT osteoclasts (Figure 3.9). These data suggest that Arf loss results in
a decrease in apoptosis during osteoclastogenesis in vitro. This result may, at least
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partially, explain why we observe enhanced osteoclast number and/or size upon Arf loss.
Finally, given the well-characterized p53-dependent role of ARF tumor suppression, we
wanted to know if enhanced osteoclastogenesis upon Arf loss is dependent upon p53. We
hypothesized that if Arf loss results in enhanced osteoclastogenesis as a result of
decreased p53 activity, then p53-/- cells will phenocopy Arf -/- cells. Therefore, we isolated
bone marrow macrophages from p53-/- mice and differentiated them alongside Arf -/macrophages. As we expected, Arf loss resulted in enhanced osteoclast number compared
to WT cells. However, p53 loss had no affect on the number of osteoclasts as they were
comparable to WT (Figure 3.10).

Protein synthesis upon Arf loss during osteoclastogenesis
As previously mentioned, it is possible that Arf loss results in increased osteoclast
number and size as a result of enhanced protein synthesis. Given that we have observed
enhanced protein synthesis following Arf loss in mitotic cells, we wanted to determine if
Arf -/- cells exhibit elevated levels of protein synthesis during osteoclastogenesis. We
began addressing this question by determining whether ARF colocalizes with
nucleophosmin (NPM) in WT osteoclasts, as previous reports show that ARF’s ability to
interact with NPM plays a significant role in controlling protein synthesis. In Figure 3.11,
we demonstrate that ARF and NPM do, in fact, colocalize in WT osteoclasts. Therefore,
we moved forward by measuring the incorporation of 35S-methionine into newlysynthesized proteins. In macrophages, we observed no differences in protein synthesis
(except at t=4h) between wild-type and Arf -/- cells (Figure 3.12a). However, in both preosteoclasts and osteoclasts, protein synthesis was significantly enhanced upon Arf loss
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relative to WT cells (Figure 3.12b,c). In mature osteoclasts (day 5), Arf loss
approximately doubled the amount of protein synthesis by 8 hours post-35S pulse (Figure
3.12c). In pre-osteoclasts, we again measured nearly a 2-fold increase in protein synthesis
by 8 hours post-35S pulse (Figure 3.12b). Furthermore, we noted that the overall highest
levels of protein synthesis, regardless of genotype, were occurring during the preosteoclast stage of differentiation (day 3) (Figure 3.12b). Therefore, we decided to focus
our attention on the differences between WT and Arf

-/-

pre-osteoclasts when assessing

ribosome output. The relative amount of actively-translating ribosomes was measured by
freezing mRNAs onto actively-translating ribosomes with cycloheximide treatment,
separating pre-osteoclast cytosolic fractions over a sucrose gradient, and reading the
amount of RNA at an absorbance of 254nm. Using this technique, the activelytranslating ribosomes or polysomes, appear on the far right of the trace. As shown in
Figure 3.13, we noted a slightly larger pool of polysomes in Arf -/- pre-osteoclasts relative
to WT pre-osteoclasts. To verify the significance of this slight change in the two profiles,
we report the ribosome profiles between WT cells on a pure B6 background and Arf -/cells on a mixed B6/129 background. Previous data from our lab has shown that even a
change in the genetic background can dramatically alter the ribosome profiles in mice of
the same genotype (unpublished data). Our profiles demonstrate that there is no
difference in ribosome output between WT (B6) and Arf -/- (B6/129) BMMs (Figure
3.14a), pre-osteoclasts (Figure 3.14b), and osteoclasts (Figure 3.14c), indicating that the
difference we observed in Figure 3.13 is biologically meaningful. Taken together, the
data suggests that we are, at least in part, observing enhanced levels of protein synthesis
upon Arf loss as a result of an increased pool of actively-translating polysomes. More
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importantly, this data supports the idea that Arf loss enhances osteoclastogenesis as a
result of elevated protein synthesis. Finally, we have previously made a correlation
between an increase in the number of AgNORs and enhanced protein synthesis upon Arf
loss in mitotic mouse embryonic fibroblasts (Apicelli et al., 2008). Therefore, we wanted
to determine if the number of AgNORs per nucleus is increased upon Arf loss during
osteoclastogenesis. Results show that Arf loss does not alter the number of AgNORs in
BMMs (Figure 3.15a), pre-osteoclasts (Figure 3.15b), and osteoclasts (Figure 3.15c)
relative to WT cells.

Examining the effects of osteoclast Arf loss in vivo
Finally, we wanted to determine if the effects we had observed upon Arf loss in
vitro translated to differences in bone resorption in vivo. Initially, we planned to create an
osteoclast-specific knockout of Arf by breeding Arf fl/fl and Ctsk Cre/+ mice. However, our
breedings resulted in germline loss of Arf (see Chapter 2). As an alternative approach, we
generated radiation chimeras by lethally irradiating WT mice and subsequently
transplanting them with WT or Arf -/- bone marrow. This allowed us to examine Arf -/osteoclasts in the presence of WT osteoblasts, which was necessary given the previously
published data demonstrating that germline Arf loss enhances osteoblastogenesis and
osteoblast activity in vivo resulting in an overall increase in bone volume (Rauch et al.).
Three weeks following the transplant, bone resorption was assessed by vivaCT (Figure
3.16). Initial vivaCT results showed no difference in bone volume between mice that
received WT bone marrow and mice that received Arf -/- bone marrow (Figure 3.17). We
therefore decided to challenge our radiation chimeras by injecting them with RANKL to
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stimulate bone resorption. Our method of RANKL injection was based on a recent study
demonstrating that three consecutive daily doses of various concentrations of RANKL
was enough to cause significant bone resorption (Tomimori et al., 2009). To confirm this
method, we first injected WT mice with either PBS or 2mg/kg RANKL for three
consecutive days. The mice were imaged before beginning the series of injections and
1.5h following the final injection to assess bone loss. Our data demonstrate that three
consecutive daily doses of 2mg/kg RANKL causes nearly 50 % bone loss (Figure 3.18).
Ultimately, we decided to challenge our radiation chimeras with three consecutive daily
doses of 1mg/kg RANKL and imaged them before the series of RANKL injections and
1.5h following the final injection as outlined in Figure 3.19. Representative 3D images of
reconstructed tibias before and after RANKL stimulation are shown in Figure 3.20a.
These images demonstrate that mice with Arf -/- osteoclasts resorb more bone compared to
mice with WT osteoclasts. The difference in trabecular bone volume (reported as bone
volume/total volume) following RANKL stimulation between mice that received a WT
transplant and mice that received an Arf -/- transplant was blindly quantified based on
vivaCT images of tibias. The data show that Arf loss results in a significant decrease in
bone volume relative to WT, suggesting that Arf loss in osteoclasts enhances bone
resorption upon RANKL stimulation in vivo (Figure 3.20b). Furthermore, Arf loss causes
a corresponding decrease in trabecular number following RANKL stimulation, which is
indicative of enhanced bone resorption (Figure 3.20c). An increase in trabecular number
is often correlated with a decrease in trabecular spacing given that the more bone within a
defined area, the less space there is between the bones. Our results follow this logic and
demonstrate a significant increase in trabecular spacing in mice that received an Arf -/-
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transplant relative to mice that received a WT transplant (Figure 3.20d). Finally, vivaCT
analysis indicates that there is a significant decrease in bone mineral density in the
absence of Arf (Figure 3.20e). To determine if there are more osteoclasts in mice
receiving an Arf -/- transplant, tibias of mice were removed and TRAP-stained following
the final vivaCT scan. The number of osteoclasts in a defined area of the tibias was
blindly quantified. Our data show that Arf loss significantly increases the number of
osteoclasts in vivo, which supports our in vitro results (Figure 3.21). As a whole, our in
vivo data suggests that Arf loss enhances bone resorption due, at least in part, to an
increase in osteoclast number.
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3.5 Discussion
ARF has long been appreciated as a protein that is upregulated in response to
oncogenic stress (Sherr, 2001). Upon induction, ARF is known to impede the ability of
MDM2 to negatively regulate the p53 tumor suppressor (Weber et al., 1999), a function
originally thought to be the sole mechanism of ARF tumor suppression. However, we
now know that ARF also suppresses tumorigenesis by mechanisms that are independent
of its ability to regulate p53 (Weber et al., 2000a). In fact, there are nearly 30 purported
ARF-interacting proteins that may well be playing a role in advancing cell growth and/or
proliferation, and it will be exciting to see future results that further define the
significance of their interactions with ARF (Sherr, 2006). Our lab has focused on the
ARF-interacting protein, nucleophosmin (NPM). We have demonstrated that ARF’s
ability to impede the nucleocytoplasmic shuttling of NPM is also a means by which cell
cycle progression in limited (Brady et al., 2004). NPM is necessary for the export of
newly transcribed and processed ribosomes to the cytoplasm for translation (Maggi et al.,
2008; Yu et al., 2006). Thus, ARF is able to limit the growth of a cell by prohibiting the
transport of ribosomes from the nucleus to the cytoplasm in a p53-independent manner.
Given that cell growth (i.e. protein synthesis) is necessary to maintain proper cell
division, our lab questioned whether ARF also regulates cell growth in non-dividing
cells. We hypothesized that the ability to limit protein synthesis might be more of a
teleological role of ARF even though it is more commonly recognized as a tumor
suppressor.
In parallel to questioning the role of ARF in non-dividing cells, a number of
reports were surfacing that outlined roles for basal ARF. These included studies
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demonstrating ARF’s p53-independent role in limiting the proliferation of mural cells
within the developing eye and ARF’s p53-independent role in regulating the survival of
spermatocytes during male germ cell development in mice (Churchman et al.; Gromley et
al., 2009; McKeller et al., 2002; Silva et al., 2005). The importance of basal ARF in
regulating these two functions is underscored by the fact that Arf -/- mice are blind and
males have a low sperm count. Given our previous work showing that ARF acts a tumor
suppressor by inhibiting NPM and thus protein synthesis, we were first interested in
determining whether basal ARF can also regulated these functions. We have since
demonstrated that basal ARF limits ribosomal DNA (rDNA) transcription, rRNA
processing, and ribosomal export to the cytoplasm via NPM to ultimately maintain a
proper rate of protein synthesis in dividing cells (Apicelli et al., 2008). Given this finding,
we were poised to answer the following question: does basal ARF regulate protein
synthesis in non-dividing cells?
Here, we used osteoclasts as a model because they are fully differentiated, nondividing cells. In route to becoming mature and functional, osteoclasts are signaled to
upregulated the production of proteins required for bone degradation, implying a
requirement for protein synthesis even as they near maturation (Teitelbaum and Ross,
2003). In vitro, osteoclasts can be differentiation from bone marrow macrophages. In this
study, we demonstrate that bone marrow macrophages derived from Arf -/- mice and
allowed to differentiate in vitro result in the production of more and bigger osteoclasts
when plated at the same density as wild-type macrophages, a finding that is supported by
previous studies using slightly different concentrations of osteoclastogenic cytokines and
an alternative approach to quantification (Apicelli et al., 2008). We further show in this
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report that enhanced osteoclastogenesis upon Arf loss is complimented by the premature
appearance of two proteins important that are necessary for proper osteoclast function:
tartrate-resistant acid phosphatase (TRAP) and Cathepsin K. In fact, in the absence of
either TRAP or Cathepsin K, mice are osteopetrotic, emphasizing their functional
importance (Hayman et al., 1996; Saftig et al., 1998). Interestingly, while mRNA levels
of TRAP and Cathepsin K are elevated during osteoclastogenesis, they do not appear any
earlier during differentiation in the absence of Arf. This suggests that ARF may be
regulating the timing of translation of these proteins. To support this hypothesis, we have
demonstrated that Arf loss results in increased protein synthesis during osteoclastogenesis
(observed in BMMs, pre-osteoclasts, and osteoclasts). This is, at least in part, due to
elevated amounts of actively-translating ribosomes in pre-osteoclasts upon Arf loss. By
isolating the mRNAs from the polysomes of pre-osteoclasts, we plan to determine
whether Arf loss alters the amount of TRAP and Cathepsin K mRNA translation at a
specific time point during osteoclastogenesis.
Our in vitro data also suggests that enhanced osteoclastogenesis upon Arf loss is
independent of ARF’s ability to regulate p53. This finding is supported by a previous
report suggesting that osteoclastogenesis is only enhanced by p53 loss in vivo due to the
coupling of osteoblast and osteoclasts (Wang et al., 2006). Specifically, it has been
reported that p53 regulates the osteoblast transcription factor osterix (Wang et al., 2006).
Osterix is important for the upregulation of M-CSF transcription, a cytokine known to be
important for cell proliferation and survival during osteoclastogenesis. However, in vitro
studies have shown that the effects of p53 on osteoclastogenesis are not cell autonomous
(Wang et al., 2006); in fact, we found that p53-/- osteoclasts appear no different than wild-
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type osteoclasts in vitro. This finding follows the other functions that have been reported
for basal ARF in that they are all p53-independent and suggests that ARF only exerts its
p53-dependent functions in the presence of oncogenic stress. We also show that ARF’s
ability to limit osteoclastogenesis is independent of proliferation. While we initiated this
study knowing that any observed effects of Arf loss on the function of mature osteoclasts
would intrinsically be independent of proliferation, given that mature osteoclasts do not
divide, it remained unclear whether enhanced osteoclastogenesis in the absence of Arf
was due in part to increased proliferation of osteoclast precursors. Of the proliferation
experiments we show here, the most important in this regard is the finding that there is no
difference in proliferation of osteoclast precursors following the addition of RANKL.
This data suggests that we do not see enhanced numbers of osteoclasts on day 5 of
osteoclastogenesis as a result of enhanced precursor proliferation after seeding the cells
for differentiation. In contrast, we did observe a decrease in apoptosis in the absence of
Arf, which was most prominent on day 7 of osteoclastogenesis, suggesting that Arf loss
extends the lifespan of osteoclasts in vitro. It is possible that the small, yet significant,
changes in apoptosis on days 3 and 4 of osteoclastogenesis contribute to the enhanced
numbers of mature osteoclasts on day 5 as well as the increases we have observed in
protein synthesis on days 3 and 5 of osteoclastogenesis. However, it is unlikely that the
observed differences in apoptosis completely explain enhanced osteoclastogenesis or
protein output given that the levels of apoptosis are very low on days 3 and 4 of
osteoclastogenesis relative to day 7. To confirm this, we will need to assess protein
synthesis and day 5 osteoclast numbers after lifting and reseeding equal numbers of
osteoclast precursors on day 3 of osteoclastogenesis. Finally, it will be important to
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determine whether Arf loss enhances the function of osteoclasts on a per cell basis, and
we are currently designing experiments to assess this in vitro by quantifying actin rings
and bone resorption of osteoclasts that have been lifted and reseeded as pre-osteoclasts.
Finally, we have now demonstrated that Arf loss in osteoclasts results in increased
bone resorption in vivo. Given that basal ARF has also been demonstrated to limit
osteoblastogenesis and osteoblast activity in vivo (Rauch et al.), we assessed the effects
of in vivo Arf loss in osteoclasts in the context of wild-type osteoblasts by generating
radiation chimeras. The radiation chimeras have allowed us to assess cell autonomous
effects of Arf loss in osteoclasts in the sense that we can exclude any effects due to the
coupling of osteoblasts and osteoclasts. Furthermore, we have observed an increase in the
number of osteoclasts present in mice that received bone marrow transplants from Arf -/mice relative to those that received bone marrow from wild-type mice. This in vivo data
supports the enhanced osteoclastogenesis and increased osteoclast number that we have
observed in vitro. Taken together, our in vivo data suggests that the effects of Arf loss
during osteoclastogenesis we observed in vitro are physiologically-relevant.
These findings represent a new role for basal ARF in regulating
osteoclastogenesis. More importantly, they are the first to demonstrate a role for basal
ARF in regulating cell growth in a p53-independent and proliferation-independent
context. It will be important to determine whether this function of ARF in
osteoclastogenesis is relevant in other cell types and is representative of a teleological
role for ARF. In terms of tumorigenesis, it also suggests that basal ARF may be limiting
protein synthesis and, upon induction by oncogenic stress, shifts its focus to regulating
p53 activity. Our lab has previously demonstrated that ARF preferentially binds to
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MDM2 over NPM (Brady et al., 2004). Moreover, ARF uses the same resides to interact
with both MDM2 and NPM (Brady et al., 2004; Weber et al., 2000b). With that in mind,
it remains to be determined how, in the absence of oncogenic stress, such low levels of
ARF are regulating protein synthesis if at least a partial pool of ARF is bound by MDM2.
This might partially be explained by recent studies suggesting that ARF can regulate the
sumoylation of NPM (Kuo et al., 2008; Tago et al., 2005) . It is possible such a
modification controls the activity of NPM rather than needing ARF to constantly be
bound to NPM . Alternatively, the cell might somehow signal ARF to focus its attention
on protein synthesis regulation under normal conditions and restrain MDM2 during
oncogenic stress. Furthermore, the role of basal ARF in regulating protein synthesis could
conceivably be important in preventing tumorigenesis in the face of oncogenic
stimulation. We would hypothesize that a cell with unrestrained protein synthesis
becomes more transformable over time as it increases its levels of unwarranted proteins,
and our lab is currently designing experiments to test this possibility both in vitro and in
vivo.
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Figure 3.1.
Genotyping and immunoblotting confirm the presence of ARF in wild-type
osteoclasts. Bone marrow macrophages (BMMs) were isolated from wild-type and Arf -/mice and differentiated in vitro in the presence of M-CSF and RANKL for 5 days. Both
DNA and protein were isolated from day 5 osteoclasts. (A) The absence of exon1β by
genotyping confirms that mature OCs are void of Arf. (B). Day 5 OCs derived from wildtype and Arf -/- BMMs immunoblotted for ARF. Cyclin D is loading control.
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Figure 3.2.
Arf loss enhances osteoclastogenesis in vitro. Bone marrow macrophages were isolated
from either wild-type or Arf-null mice. Equal numbers of macrophages were plated in 48well dishes in the presence of M-CSF (1/100 vol) and RANKL. After 5 days in the
presence of osteoclastogenic media, cells were fixed and TRAP-stained. WT = blue bars
and Arf -/- = red bars (A). Three representative 4X images from both wild-type and Arf -/day 5 TRAP-stained osteoclasts. (B) Multinucleated TRAP-positive osteoclasts were
blindly counted in three fields of each well and averaged. There are significantly more
osteoclasts present in the absence of Arf ( p ≤ 0.05). (C) Three fields in each well of
TRAP-stained multinucleated osteoclasts were blindly assessed for the percent area
covered by osteoclasts and averaged. The absence of Arf results in a significantly greater
area covered by osteoclasts relative to wild-type ( p ≤ 0.05). (D) Average osteoclast size
was determined by dividing the total area covered by osteoclasts by the total number of
osteoclasts in that field (inches^2). The absence of Arf results in significantly larger
osteoclasts relative to wild-type ( p ≤ 0.05).
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Figure 3.3
Arf-null macrophages are hypersensitive to RANKL. Bone marrow macrophages were
isolated from either wild-type or Arf-null mice. Equal numbers of macrophages were
plated in 48-well dishes in the presence of M-CSF and varying concentrations of
RANKL. After 5 days in the presence of osteoclastogenic media, cells were fixed and
TRAP-stained. WT = blue bars and Arf -/- = red bars (A) Representative 4X images of
wild-type and Arf-null cells under each tested concentration of RANKL. (B)
Multinucleated TRAP-positive osteoclasts were blindly counted in three fields of each
well. At all concentrations of RANKL, there are significantly more osteoclasts present in
the absence of Arf ( p ≤ 0.05 at all concentrations). (C) Three fields in each well of
TRAP-stained multinucleated osteoclasts were blindly assessed for the percent area
covered by osteoclasts. At all concentrations of RANKL, the absence of Arf results in a
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significantly greater area covered by osteoclasts relative to wild-type ( p ≤ 0.05 at all
concentrations). (D) Average osteoclast size was determined by dividing the total area
covered by osteoclasts by the total number of osteoclasts in that field (inches^2). At all
concentrations of RANKL, the absence of Arf results in significantly larger osteoclasts
relative to wild-type ( p ≤ 0.05 at all concentrations).
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Figure 3.4.
Arf loss results in increased levels of Cathepsin K and TRAP mRNA during
osteoclastogenesis. Bone marrow macrophages from either wild-type or Arf -/- mice were
differentiated in vitro with M-CSF and 50ng/mL RANKL. RNA was isolated from bone
marrow macrophages (before RANKL addition) and each day after the addition of
RANKL for 5 days. Equal amounts of RNA were used to generate cDNA by reverse
transcription. Equal amounts of cDNA were used to assess the levels of Cathepsin K
mRNA (left figure) and TRAP mRNA (right figure) by quantitative RT-PCR. WT = blue
bars, Arf -/- = red bars. On days 4 and 5 (post-RANKL), loss of Arf significantly increases
the amount of both Cathepsin K mRNA (left) and TRAP mRNA (right) ( p ≤ 0.05 on
days 4 and 5 only).
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Figure 3.5.
Arf loss results in increased protein levels of Cathepsin K and TRAP during
osteoclastogenesis. Bone marrow macrophages from either wild-type or Arf -/- mice were
differentiated in vitro with M-CSF and 50ng/mL RANKL. Total protein was isolated
each day after the addition of RANKL for 5 days. Equal amounts of protein were
separated by SDS-PAGE. Membranes were probed for Cathepsin K, TRAP, and βtubulin (control). Protein bands were quantified by densitometry. Levels of Cathepsin K
were first normalized to β-tubulin and fold changed was subsequently assessed
calculating the fold change for each day relative to WT day 3. Levels of TRAP were first
normalized to β-tubulin and fold changed was subsequently assessed calculating the fold
change for each day relative to WT day 3.
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Figure 3.6.
Enhanced fusion during osteoclastogenesis does not explain the increase in
osteoclast size upon Arf loss. Bone marrow macrophages from either wild-type or Arf -/mice were differentiated in vitro on glass coverslips in the presence of M-CSF and
50ng/mL RANKL. After 6 days in the presence of osteoclastogenic media, cells were
fixed and stained with DAPI to demarcate nuclei. Nuclei numbers were blindly counted
in 100 osteoclasts of each genotype. WT = blue bars, Arf -/- = red bars. Difference is not
statistically significant.
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Figure 3.7.
Arf loss increases bone resorption by osteoclasts in vitro. Bone marrow macrophages
from either wild-type or Arf -/- mice were differentiated in vitro on bovine bone slices in
the presence of M-CSF and 50ng/mL RANKL. After 8 days in the presence of
osteoclastogenic media, cell were removed and bone slices were incubated with
peroxidase-conjugated wheat germ agglutinin followed by 3,3-diaminobenzidine to
visualize areas of bone resorption. (A) Two representaive fields from each genotype
(dark brown indicates areas of bone resorption) (B) Resorptive area (pits) were blindly
quantified by determining the average of four fields from each bone slice. Difference is
statistically significant ( p ≤ 0.05).
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Figure 3.8.
Proliferation of osteoclast precursors in not enhanced upon Arf loss. Bone marrow
macrophages from either wild-type or Arf -/- mice were differentiated in vitro on glass
coverslips either in the presence of M-CSF (BMMs) or M-CSF and 50ng/mL RANKL
(osteoclasts). Cells were incubated for 24h with BrdU to assess proliferation. (A) Cells
were fixed as macrophages (pre-RANKL) and 24h after RANKL addition (postRANKL). (B) Cells were fixed 3 and 4 days post-RANKL as proliferation controls. All
fixed cells were then incubated with an antibody recognizing BrdU and DAPI to
demarcate nuclei. At least100 nuclei were blindly assessed for BrdU for each genotype
and at each time point. WT = blue bars, Arf -/- = red bars. All differences are not
statistically significant.
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Figure 3.9.
Arf loss extends the lifespan of osteoclasts in vitro. Bone marrow macrophages from
either wild-type or Arf -/- mice were seeded at 5000 cells/well in 96-well dishes and
differentiated in the presence of M-CSF and 50ng/mL RANKL. On days 4, 5, 6, and 7
after the addition of RANKL, cell death was assessed by an ELISA, which detects
cytoplasmic histone-associated DNA fragmentation Absorbance was measured at
405nm. WT = blue bars and Arf -/- = red bars. Arf loss results in a statistically significant
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decrease in apoptosis on days 4, 5, and 7 ( p ≤ 0.05). The difference observed on day 6 is
not statistically significant.
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Figure 3.10.
p53 loss does not phenocopy Arf loss during osteoclastogenesis in vitro. Bone marrow
macrophages from either wild-type, Arf -/- , or p53-/- mice were differentiated in 48-well
dishes in the presence of M-CSF and 50ng/mL RANKL. After 5 days in the presence of
osteoclastogenic media, cells were fixed and TRAP-stained. (A) Osteoclast number was
blindly quantified by counting TRAP-positive multinucleated cells in two fields of each
well at a 4X magnification. The two fields were averaged for each well and reported as
number of osteoclasts per 4X image. There were significantly more osteoclasts derived
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from Arf -/- macrophages relative to both wild-type and p53-/- ( p ≤ 0.05). The difference
in osteoclast number between wild-type and p53-/- is not statistically significant. (B)
Representative TRAP-stained 4X images are shown below their respective genotypes.
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Figure 3.11.
ARF colocalizes with NPM in nucleoli of wild-type osteoclasts. Bone marrow
macrophages from either wild-type mice were differentiated in vitro on glass coverslips
in the presence of M-CSF and 50ng/mL RANKL. After 6 days in the presence of
osteoclastogenic media, cells were fixed and stained for ARF and NPM followed by
FITC- and rhodamine-conjugated secondary antibodies. DAPI was used to demarcate
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nuclei. ARF is visualized in red channel (top images). NPM is visualized in green
channel (middle images). Merged images (bottom) represent the red, green, and blue
channels.
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Figure 3.12.
Loss of Arf results in enhanced protein synthesis during osteoclastogenesis. Bone
marrow macrophages from either wild-type or Arf -/- mice were plated in 6-well dishes in
the presence of only M-CSF (BMMs) or M-CSF and 50ng/mL RANKL (pre-OCs and
OCs). All cells were starved of methionine and cysteine for 30min prior to labeling at the
appropriate time point during differentiation (3 days post-RANKL for pre-OC and 5 days
post-RANKL for OCs). Following starvation, cells were pulsed with 150 μCi of

35

S-

mehtionine for the indicated times (2, 4, or 8 hours). The first time point (t=0) was
harvested immediately after the pulse. Following the pulse, cells were washed with cold
phosphate-buffered saline and then lysed with 1% Triton X-100 buffer. Protein was
precipitated from cell lysates using 10% tricholoroacetic acid and pellets were analyzed
by liquid scintillation counting to quantify the incorporated counts per million. WT =
145

blue, Arf -/- = red. (A) Protein synthesis in bone marrow macrophages (Arf -/- only
statistically higher than wild-type at t = 4h, p ≤ 0.05). (B) Protein synthesis in preosteoclasts (Arf -/- statistically higher than wild-type at t = 4h and t = 8h, p ≤ 0.05). (C)
Protein synthesis in osteoclasts (Arf -/- statistically higher than wild-type at t = 2, t = 4h,
and t = 8, p ≤ 0.05).
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Figure 3.13.
Loss of Arf results in enhanced ribosome output in pre-osteoclasts. Bone marrow
macrophages from either wild-type or Arf -/- mice were differentiated in 100mm dishes
for 3 days in the presence of M-CSF and 50ng/mL RANKL. Cells were then treated with
50ug/mL cycloheximide to freeze actively-translating ribosomes onto mRNAs. 3 x 106
cells were lysed and cytosolic fractions were separated by centrifugation over a
continuous sucrose gradient. RNA absorbance was continuously monitored at 254nm to
detect ribosomal subunits. WT = blue bars, Arf -/- = red bars.
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Figure 3.14.
Ribosome output is not different between wild-type and Arf -/ - cells during
osteoclastogenesis when mice are on different backgrounds, indicating the sensitivity
of generating ribosome profiles to assess ribosome output. Bone marrow macrophages
from either wild-type mice on a B6 background or Arf -/- mice on a B6/129 background
were differentiated in 100mm dishes either in the presence of M-CSF alone (BMMs) or
both M-CSF and 50ng/mL RANKL. Cells were then treated with 50ug/mL
cycloheximide to freeze actively-translating ribosomes onto mRNAs at the appropriate
days following the addition of RANKL ( 3 days post-RANKL for pre-osteoclasts and 5
days post-RANKL for osteoclasts, BMMs not given RANKL but harvested 24h after
plating in the presence of M-CSF). 3 x 106 cells were lysed and cytosolic fractions were
separated by centrifugation over a continuous sucrose gradient. RNA absorbance was
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continuously monitored at 254nm to detect ribosomal subunits. WT = blue bars, Arf -/- =
red bars. (A) Ribosome profiles of BMMs (B) Ribosome profiles of pre-osteoclasts (C)
Ribosome profiles of osteoclasts
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Figure 3.15.
Arf loss does not alter the number of AgNORs per nucleus during
osteoclastogenesis. Bone marrow macrophages from either wild-type or Arf -/- mice were
differentiated in 100mm on coverslips in the presence of M-CSF alone (BMMs) or both
M-CSF and 50ng/mL RANKL (pre-osteoclasts and osteoclasts). At the appropriate time
during osteoclastogenesis (24h post-plating for BMMs, 3 days post-RANKL for preosteoclasts, and 5 days post-RANKL for osteoclasts) cells were fixed and processed to
visualize AgNORs, and mounted on slides. AgNOR numbers in at least 50 nuclei on each
coverslip for each genotype were blindly quantified. WT = blue bars, Arf -/- = red bars.
(A) Average number of AgNORs per nucleus in BMMs (difference is not statistically
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significant). (B) Average number of AgNORs per nucleus in pre-osteoclasts (difference is
not statistically significant). (C) Average number of AgNORs per nucleus in osteoclasts
(difference is not statistically significant).
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Figure 3.16.
Outline of initial experimental set-up to determine the role of ARF in osteoclasts in
vivo. 24 hours after irradiating 28 7 week-old wild-type male mice, whole bone marrow
was harvested from either wild-type or Arf -/- mice and 1 x 106 cells were injected
intravenously into the irradiated mice. 13 mice received wild-type bone marrow, 13
received Arf -/- bone marrow, and 2 did not receive a transplant to control for the success
of lethal irradiation. Mice that did not receive a transplant died 2 weeks following the
irradiation. The remaining 26 mice were imaged by vivaCT 3 weeks following the
irradiation and transplant.
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Figure 3.17.
Initial BV/TV results indicate that radiation chimeras must be challenged with
RANKL. Radiation chimeras were subjected to vivaCT 3 weeks following the transplant
to determine bone volume. There is no significant difference between wild-type mice that
received bone marrow from wild-type donors and wild-type mice that received bone
marrow from Arf -/- donors.
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Figure 3.18.
Three consecutive daily doses of 2mg/kg RANKL given intraperitoneally causes a
significant reduction in bone volume. Pre-RANKL bone volume was assessed by
vivaCT anlysis for both groups less than 1 week prior to the initial injection of RANKL
(blue bars). Three age-matched wild-type male mice were subsequently intraperitoneally
injected daily with 2mg/kg RANKL for 3 consecutive days. Controls (n = 3) received
daily intraperitoneally injections of equivalent volumes of PBS (based on individual
weights) for 3 consecutive days. Post-RANKL bone volume was assessed by vivaCT
analysis 1.5h following the final injection (red bars). The difference between preRANKL and post-RANKL BV/TV (bone volume/total volume) is not statistically
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significant following PBS injections. The difference between pre-RANKL and postRANKL BV/TV is statistically significant ( p ≤ 0.05)
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Figure 3.19.
Outline of final experimental set-up to determine the role of ARF in osteoclasts in
vivo. (A) 24 hours after irradiating 28 7 week-old wild-type male mice, whole bone
marrow was harvested from either wild-type or Arf -/- mice and 1 x 106 cells were injected
intravenously into the irradiated mice. 13 mice received wild-type bone marrow, 13
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received Arf -/- bone marrow, and 2 did not receive a transplant to control for the success
of lethal irradiation. Mice that did not receive a transplant died 2 weeks following the
irradiation. The remaining 26 mice were subjected to a pre-scan by vivaCT 3 weeks
following the irradiation and transplant (pre vivaCT). One week following the pre-scan,
mice were challenged with RANKL and subsequently imaged by vivaCT (post vivaCT).
(B) Beginning at 11 weeks of age, mice were intraperitoneally injected with 3
consecutive daily doses of 1mg/kg RANKL (8 mice received WT bone marrow and
RANKL, 8 mice received Arf -/- bone marrow and RANKL). Control mice were
intraperitoneally injected with 3 consecutive daily doses of PBS (5 mice received WT
bone marrow and PBS, 5 mice received Arf -/-bone marrow and PBS). 1.5h following the
last RANKL (or PBS) injection, mice were imaged by vivaCT (post vivaCT).
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Figure 3.20.
Loss of Arf in osteoclasts results in increased bone resorption in vivo following
RANKL stimulation. Pre-RANKL bone parameters were assessed by vivaCT analysis
for both groups less than 1 week prior to the initial injection of RANKL. All mice were
subsequently intraperitoneally injected daily with 1mg/kg RANKL for 3 consecutive days
(n = 8 per group). Controls received daily intraperitoneally injections of equivalent
volumes of PBS (based on individual weights) for 3 consecutive days. Post-RANKL
bone parameteres were assessed by vivaCT analysis 1.5h following the final injection.
For each animal, the difference between their pre-RANKL scan and post-RANKL scan
was quantified and presented as present loss or gain. Animals receiving a WT bone
marrow transplant are represented by blue bars and animals receiving an Arf -/- bone

162

marrow transplant are represented by blue bars. There were no statistically significant
differences between WT and Arf -/-bone marrow recipients injected with PBS (data not
shown). (A) Representative 3D images generated by vivaCT analysis show the trabecular
bone in the tibia of a WT (top) and Arf -/- (bottom) bone marrow recipient before and
after RANKL injection. (B) Animals receiving Arf -/- bone marrow lost significantly more
bone volume following RANKL injections relative to animals receiving WT bone
marrow ( p ≤ 0.05). (C) Animals receiving Arf -/- bone marrow had a significant decrease
in trabecular number following RANKL injections relative to that in animals receiving
WT bone marrow ( p ≤ 0.05). (D) Animals receiving Arf -/- bone marrow had a
significant increase in trabecular spacing following RANKL injections relative to that in
animals receiving WT bone marrow ( p ≤ 0.05). ). (E) Animals receiving Arf -/- bone
marrow had a significant decrease in bone mineral density following RANKL injections
relative to that in animals receiving WT bone marrow ( p ≤ 0.05).
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Figure 3.21.
Loss of Arf in osteoclasts results in an increase in osteoclast number in vivo following
RANKL stimulation. Radiation chimeras were intraperitoneally injected daily with
1mg/kg RANKL for 3 consecutive days (n = 8 per group). Following the final injection
of RANKL and vivaCT scan, tibias were harvested and formalin-fixed. Bones were then
decalcified and incubated in increasing amounts of EtOH. Decalicified histological
sections of proximal tibias were TRAP-stained and the number of OCs were blindly
quantified in each section. Mice receiving WT bone marrow are represented by the blue
bar and mice receiveing Arf -/- bone marrow are represented by the red bar. Difference is
statistically significant ( p ≤ 0.05).
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Chapter 4
Future Directions
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4.1 Short-term future directions

Determine whether wild-type BMMs eventually “catch-up” with Arf -/- BMMs during
osteoclastogenesis.
Our data from Chapter 3 suggest that Arf loss enhances osteoclastogenesis
resulting in an increase in osteoclast number 5 days post-RANKL. In some cases, I have
allowed both wild-type and Arf -/- macrophages to differentiate in osteoclastogenic media
for 6 or more days. During these experiments, I have never observed a wild-type
osteoclast phenotype that resembles that of Arf -/- osteoclasts. Specifically, I have not
observed wild-type day 6 osteoclasts that phenocopy Arf -/- day 5 osteoclasts. However,
this experiment remains to be formally completed and quantified. In thinking about how
the results of this experiment might affect overall osteoclast number, we must also
consider our results demonstrating that Arf loss extends the lifespan of osteoclasts in
vitro. Therefore, even if wild-type BMMs eventually “catch-up” on day 6 to phenocopy
their Arf -/- counterparts, they will still undergo apoptosis before the Arf -/- cells.
Ultimately, this means that at any given time, there will always be more Arf -/- osteoclasts.
Furthermore, the number of osteoclasts is one component in the overall output of
osteoclast activity (the other being the function of osteoclasts on a per cell basis as will be
discussed in the following section), which means that in the context of equal numbers of
precursors and identical concentrations of osteoclastogenic cytokines, there should
always be more osteoclast output in the absence of Arf.
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Determine whether Arf loss results in increase osteoclast function in vitro
As mentioned above, there are two components to overall osteoclast output (i.e.
bone resorption): osteoclast number and osteoclast function. It remains to be determined
whether Arf loss increases the function of osteoclasts on a per cell basis. Our lab has
previously published that Arf -/- cells 3 days post-RANKL have more TRAP activity than
equal numbers of wild-type cells post-RANKL (Apicelli et al., 2008), suggesting that Arf
loss results in enhanced osteoclast function on a per cell basis. To further support this
finding, I propose to monitor osteoclast function in vitro by quantifying actin rings and
bone resorption. Specifically, day 3 wild-type and Arf -/- pre-osteoclasts can be lifted and
replated at equal densities on bovine bone slices. After 24h, the osteoclasts can be fixed
on bone and stained for actin rings. Actin rings are areas of active bone resorption. There
may be multiple actin rings per osteoclasts. One can quantify total area of active
resorption per total cell area to get a percentage of active area resorption. While useful,
this experiment does not necessarily take into account the amount of enzymes being
secreted in each area of active resorption. Therefore, we must assess bone resorption in
parallel. This could be quantified by either determining the area of bone resorption after
removing the osteoclasts (pit assay), by quantifying the amount of collagen fragments
released into the culture media, or both.

Further examine the effects of Arf loss on mononuclear precursor fusion
One of the most prominent in vitro phenotypes of Arf -/- osteoclasts is their size.
There are two main possibilities for why Arf loss would result in an increase in osteoclast
size: (i) enhanced fusion of mononuclear precursors and (ii) excessive protein synthesis.
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It is also possible that both contribute to increased size. Our data show that Arf -/osteoclasts do not have more nuclei than wild-type osteoclasts, suggesting that increased
size is not due to enhanced fusion in the absence of Arf. As an alternative and more
precise way of assessing fusion, we could label the nuclei of wild-type bone marrow
macrophage with one color and the nuclei of Arf -/- bone marrow macrophages with
another color. The nuclei from each genotype could then be plated together in different
ratios for osteoclastogenesis. Nuclei from mature osteoclasts could then be assessed. For
example, if we label wild-type nuclei red and Arf -/-nuclei green and plate wild-type: Arf -/nuclei at a ratio of 2:1, then each mature osteoclasts should have 2 red nuclei for every 1
green nucleus. This result would suggest that Arf loss does not affect mononuclear
precursor fusion. However, if mature osteoclasts present with a ratio of 2 red: 2 green,
then it would suggest that Arf loss enhances nuclear fusion. In parallel, one might also
assess DC-STAMP levels, particularly in pre-osteoclasts, as this is a protein necessary for
the fusion of precursors (Kukita et al., 2004; Yagi et al., 2005).

Determine whether the translation of TRAP and Cathepsin K mRNAs are altered in the
absence of Arf
We have shown in Chapter 3 that TRAP and Cathepsin K protein levels appear
24h early during osteoclastogenesis in the absence of Arf in vitro. Additionally, we now
know that Arf loss enhances protein synthesis during osteoclastogenesis (Apicelli et al.,
2008). It is therefore possible that Arf loss is allowing for the premature translation of
TRAP and Cathepsin K mRNAs. To test this possibility, we can isolate mRNAs from
various peaks of our pre-osteoclast ribosome profiles. mRNAs undergoing higher rates of
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translation will be shifted to the right on the polysome profiles in Arf -/- pre-osteoclasts
relative to wild-type pre-osteoclasts. It may also be necessary to assess the levels of
TRAP and Cathepsin K mRNAs on the polysome during day 2 of osteoclastogenesis
since we first begin to see levels of both proteins appear on day 3 of osteoclastogenesis. It
is possible that using day 2 ribosome profiles, we may detect TRAP and Cathepsin K
mRNAs on the polysome only in the absence of Arf.

Genetically determine whether enhanced osteoclastogenesis upon Arf loss is dependent
on NPM
Our lab has previously reported that ARF can inhibit the nucleocytoplasmic
shuttling activity of nucleophosmin (NPM) (Brady et al., 2004). We also know that NPM
is essential for ribosome export and protein synthesis (Maggi et al., 2008; Yu et al.,
2006). Apicelli et al. demonstrated that when NPM is knocked down in Arf -/macrophages, the Arf -/- in vitro osteoclast phenotype is reverted to that of wild-type
osteoclasts (Apicelli et al., 2008). Initially, we hoped to examine the role of NPM during
osteoclastogenesis in wild-type and Arf -/- cells by taking advantage of a recently
published small molecule inhibitor (Qi et al., 2008). The authors reported that this
inhibitor disrupts the oligomer formation of NPM, which is hypothesized to be critical for
its function given that NPM is found as an oligomer under native conditions (Herrera et
al., 1996; Namboodiri et al., 2004). Preliminary results suggested that NPM is important
for wild-type osteoclastogenesis (Figure 4.1). However, our lab has been unable to verify
by native gel electrophoresis that the small molecule inhibitor of NPM disrupt its
oligomer formation. Still, it is promising to see such a dramatic phenotype upon the
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suspected loss of NPM function. Therefore, I propose an alternative approach to
determining the role of NPM during osteoclastogenesis in both wild-type and Arf -/- cells.
To genetically determine the role of NPM in enhanced osteoclastogenesis upon
Arf loss, we have crossed Npm+/- mice with Arf -/- mice and generated the following
genotypes: Npm+/-; Arf +/+, Npm+/+; Arf -/-, and Npm+/-; Arf -/-. I would first examine the
osteoclastogenesis phenotype of all three of these genotypes in vitro to determine if loss
of one Npm allele reverses the Arf -/- osteoclastogenesis phenotype. Future studies could
also examine protein synthesis in each of these genotypes by 35S-methionine
incorporation. First of all, we need to know the osteoclastogenesis phenotype of Npm+/-;
Arf +/+ bone marrow macrophages. It has been reported that Npm+/- mouse embryonic
fibroblasts (MEFs) have lower rates of proliferation compared to wild-type MEFs at early
passage and are haploinsufficient in their control of genetic stability (Grisendi et al.,
2005). Furthermore, Npm+/- mice have accelerated oncogenesis and develop a
hematological syndrome (Grisendi et al., 2005). However, there have been no reports
demonstrating changes in osteoclastogenesis upon loss of Npm. Given that we have
shown relatively low levels of ribosome output (compared to that observed in MEFs), it
is possible that Npm+/-; Arf +/+ cells will have no defect in protein production or
osteoclastogenesis. If this is true, then we can directly compare the other two genotypes.
If unrestrained NPM activity is at least partially responsible for elevated levels of protein
synthesis observed during osteoclastogenesis upon Arf loss, then we would expect to see
a decrease in protein synthesis in Npm+/-; Arf -/- mice relative to Npm+/+; Arf -/- mice. One
could additionally examine ribosome output as well as the nucleocytoplasmic shuttling of
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ribosomes in all of these mice. Finally, it would be interesting to know if loss of one
allele of Npm in Arf -/- mice reverses the in vivo osteoclast phenotypes.
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Figure 4.1
A small molecule inhibitor of nucleophosmin (NPM) retards osteoclastogenesis in
vitro. (A) Wild-type bone marrow macrophages were plated in osteoclastogenic media in
the presence of either DMSO or a small molecule inhibitor of NPM (NPMi) and allowed
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to differentiate for 6 days. Osteoclasts are stained with TRAP. (B) Multinucleated TRAPpositive osteoclasts were quantified after 6 days. Three 4X fields were averaged from 4
individual wells. Difference is statistically significant ( p ≤ 0.05).
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Genetically demonstrate that enhanced osteoclastogenesis in the absence of Arf is a
result of increase protein synthesis
One of the major goals of this thesis has been to understand the role of ARF in
regulating protein synthesis. While the previous experiment would strongly implicate
ARF in impeding protein synthesis through the regulation of NPM, it does not rule out
the possibility that ARF is prohibiting other functions that have been attributed to NPM
and are not directly related to shuttling ribosomes and promoting protein synthesis
(Grisendi et al., 2006; Okuwaki, 2008). Therefore, we have also crossed Arf -/- mice with
mice containing a mutated allele of ribosomal protein L24. These mice are noted for their
characteristic white belly spot and kinked tail and are thus referred to as the Belly Spot
and Tail (Bst) mice (Oliver et al., 2004). Rpl24Bst/+ cells have decreased rates of protein
synthesis and proliferation relative to wild-type cells (Oliver et al., 2004). Aside from the
aforementioned characteristics, the most notable phenotype of Rpl24Bst/+ mice is a retinal
defect (Rice et al., 1997; Rice et al., 1995; Smith et al., 2000; Tang et al., 1999).
Interestingly, they also have some skeletal deformities including a triphalangeal first
digit, an extra preaxial digit, a sixth lumbar vertebrae, and fused or wedge-shaped
hemivertebrates, which result in the kinked tail phenotype (Oliver et al., 2004).
Furthermore, homozygous loss of Rpl24 is lethal (Oliver et al., 2004).
We now have the following genotypes: Rpl24+/+; Arf -/-, Rpl24Bst/+; Arf +/+, and
Rpl24Bst/+; Arf -/-. The first experiment should be to isolate bone marrow macrophages
from each of these mice and differentiate them into osteoclasts in vitro to determine if
mutation of one Rpl24 allele can reverse the Arf -/- osteoclast phenotype. I would expect
that these osteoclasts would look more like wild-type osteoclasts and have decreased
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protein synthesis and ribosome output relative to the Arf -/- cells. If this is true, it would be
genetic evidence demonstrating a role for ARF in regulating protein synthesis during
osteoclastogenesis. Moreover, bone marrow from Rpl24Bst/+; Arf -/- could be used to
generate radiation chimeras to compare wild-type mice receiving either wild-type or
Arf -/- bone marrow transplants as we have done in Chapter 3.

Determine whether enhanced osteoclastogenesis upon Arf loss is dependent on p68
Our lab has recently isolated wild-type and Arf -/- nuclei in order to identify
proteins whose nucleolar location is altered upon loss of Arf. This screen identified p68
(DDX5), which is an RNA helicase excluded from the nucleolus in the presence of ARF
(Saporita et al., 2011). ARF prevents DDX5 from promoting ribosome biogenesis.
Furthermore, the overall role of DDX5 in protein synthesis is demonstrated by the fact
that its knockdown mimics ARF overexpression in TKO MEFs in terms of ribosome
output (Saporita et al., 2011). In vitro and in vivo transformation experiments underscore
the importance of the ARF-p68 interaction. In soft agar, Arf -/- MEFs are transformed in
the presence of oncogenic Ras. However, knockdown of p68 in Arf -/- MEFs prohibited
their transformation by Ras. Similarly, MEFs transduced with Ras and shp68 did not
form tumors when inoculated into the flanks of nude mice whereas tumors did form in
the presence of p68 (Saporita et al., 2011). Given that ARF limits protein synthesis in part
by antagonizing the function of p68 in mitotic cells, it is possible that the ARF-p68
relationship is important during osteoclastogenesis. As a preliminary experiment, I have
knocked down p68 in wild-type and Arf -/- cells during osteoclastogenesis. The data
suggest that p68 is important for enhanced osteoclastogenesis upon Arf loss as there are
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significantly less osteoclasts in the absence of Arf when p68 is knocked down relative to
Arf -/- cells transduced with a control shRNA (Figure 4.2). Future studies could further
examine the importance of p68 in enhanced osteoclastogenesis upon Arf loss by probing
the steps of ribosome biogenesis, assessing ribosome output, and quantifying protein
synthesis to determine if loss of p68 ultimately reverses the Arf -/- osteoclastogenesis
phenotype.
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Figure 4.2.
Enhanced osteoclastogenesis upon in the absence of Arf is dependent on p68
(DDX5). (A) Representative 10X images of wild-type or Arf -/- day 5 osteoclasts that
were lentivirally-transduced with either shSCRAMBLE or shDDX5. (B) Images were
blindly quantified. Asterisks represent statistically significant differences between
WT+shSCR and WT+shDDX5 or Arf -/-+shSCR and Arf -/-+shDDX5 (p ≤ 0.05).

182

4.2 Long-term future directions

Examine the role of miRNAs during enhanced osteoclastogenesis upon Arf loss
Our lab has observed that Arf loss results in the selective translation of specific
mRNAs in mouse embryonic fibroblasts (MEFs). In an effort to identify regulatory
factors that may be controlling the translation of mRNAs upon Arf loss, we have initiated
high throughput screens to assess the differences in miRNAs upon Arf loss in MEFs.
Changes in the miRNA signature of a cell could significantly modulate the translation of
various mRNAs as miRNAs are known to imperfectly base pair with target mRNAs and
repress their translation (Calin and Croce, 2006). Upon observing differences in the
miRNA prolife in MEFs, we first assessed day 5 wild-type and Arf -/- osteoclasts to see if
any of the same miRNA changes exist between both mitotic and post-mitotic cells
(Figure 4.3a). Of the tested miRNAs in day 5 osteoclasts, we were most interested in
miRNA 223, as it has been reported to downregulated in both MEFs and osteoclasts,
although it was only slightly downregulated in osteoclasts. However, it is also
particularly interesting given that a recent study has shown that is downregulated in
response to RANKL during osteoclastogenesis (Sugatani et al.). Furthermore, pre-miR223 overexpression has been shown to block the formation of TRAP-positive
multinucleated osteoclasts in vitro (Sugatani and Hruska, 2007). Together with published
results, our data indicate that Arf loss may downregulate miR-223 to promote
osteoclastogenesis. This hypothesis could be tested by overexpressing pre-miR-223 in Arf
-/-

macrophages upon plating in osteoclastogenic media. If the hypothesis is correct, I

would expect to see a decrease in osteoclastogenesis with the overexpression relative to

183

what we have observed in Arf -/- cells. Additionally, we assessed the levels of two other
miRNAs that have been reported in the osteoclast literature: miR-155 and miR-21 (Mann
et al.; Sugatani et al.). We found that both of these miRNAs were slightly elevated in preosteoclasts upon Arf loss (Figure 4.3b). This would suggest that they may positively
regulate osteoclastogenesis. In agreement with our results, Sugatani and colleagues have
published that both of these miRNAs are upregulated in response to RANKL during
osteoclastogenesis (Sugatani et al.). It would therefore be interesting to overexpress these
in wild-type macrophages to see if they enhance osteoclastogenesis. Additionally, I
would hypothesize that if they are knocked down in Arf -/- macrophages, then the
enhanced osteoclast number and size may be, at least partially, reversed.

184

A

WT and Arf-/- OCs (Day 5)
miR
132
127

Fold Change
1. 86
N/A

Taqman A rray
2. 86
1. 86

129

2. 27

2. 43

142

1. 10

---

223

1. 22

17. 02

34b

1. 93

2. 30

34c

2. 24

2. 34

182

5. 25

2.39

B

Fold Increase in Arf‐/‐ OCs

3.000
2.500
2.000
1.500
1.000
0.500
0.000
miR‐155

miR‐21

Figure 4.3
Changes in miRNAs during osteoclastogenesis. (A) Select miRNAs were assessed in
wild-type and Arf -/- day 5 osteoclasts. Fold change is Arf -/- relative to wild-type. This is
compared to results from a Taqman array done using wild-type and Arf -/- MEFs, in which
the fold change represents Arf -/- MEFs relative to wild-type MEFs. (B) Taqman assays
suggest that both miR-155 and miR-21 are elevated in Arf -/- pre-osteoclasts (day 3)
relative to wild-type pre -osteoclasts.
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Analyze the translatome of wild-type and Arf -/-osteoclasts
A central theme of this work is that Arf loss enhances protein synthesis to
accelerate osteoclastogenesis, which begs the question: which mRNAs are being
selectively translated (or not translated) when Arf is lost. Our lab and others have
observed that some mRNAs are translated at rates that do not correspond with their levels
of transcription (Pelletier et al., 2007; Rajasekhar et al., 2003). Furthermore, our lab has
assessed the translatome (see Figure 4.4 for a description of the methods used in
translatome analysis) of wild-type and Arf -/-MEFs and found 109 mRNAs that are
preferentially loaded (or unloaded) on the polysomes upon Arf loss. Additionally, we plan
to perform the same assessment using Arf -/- prostate epithelial cells. It would be
interesting to analyze the translatome of wild-type and Arf -/- pre-osteoclasts, as this is
point at which we have observed significant changes in both ribosome output and protein
synthesis during osteoclastogenesis. Not only would this data aid in the understanding of
how Arf loss enhances osteoclastogenesis, but it would also be helpful to compare the
translatomes of mitotic and post-mitotic cells. With such a comparison, we may be able
to identify mRNAs whose translation is specifically important for cell growth
independent of proliferation.
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Figure 4.4
Schematic of methods used to determine mRNAs preferentially loaded or unloaded
onto polysomes. mRNAs are "frozen" onto ribosomes by treating equal numbers of cells
with cycoleximide. The cells are then lysed and the cytosolic fractions are separated
using a sucrose density gradient. Polysome peaks will be collected and RNA from these
peaks will be isolated. The RNA is then used in a microarray analysis (Illumina Mouse 8
array analysis done at Washington University). Each of the 8 arrays contains 24,000
known genes. The data is then statistically analyzed by the Microarray Core Facility at
Washington University. All changes at the polysome are compared to changes at the total
RNA level. Figure courtesy of Len Maggi.
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